

RNA-Based Therapeutics: Current Progress and Future

Chemistry and Biology

19, 60-71

DOI: [10.1016/j.chembiol.2011.12.008](https://doi.org/10.1016/j.chembiol.2011.12.008)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Role of Exosomes/Microvesicles in the Nervous System and Use in Emerging Therapies. <i>Frontiers in Physiology</i> , 2012, 3, 228.	2.8	254
2	Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering. <i>Frontiers in Genetics</i> , 2012, 3, 154.	2.3	82
3	RNA mediated toll-like receptor stimulation in health and disease. <i>RNA Biology</i> , 2012, 9, 828-842.	3.1	90
4	Alternative splicing in human tumour viruses: a therapeutic target?. <i>Biochemical Journal</i> , 2012, 445, 145-156.	3.7	23
5	Selecting Molecular Recognition. What Can Existing Aptamers Tell Us about Their Inherent Recognition Capabilities and Modes of Interaction?. <i>Pharmaceuticals</i> , 2012, 5, 493-513.	3.8	13
6	Predicting and preventing viral escape from therapy. <i>Future Virology</i> , 2012, 7, 483-487.	1.8	0
7	siRNA and cancer immunotherapy. <i>Immunotherapy</i> , 2012, 4, 907-917.	2.0	37
8	Advanced Aqueous-Phase Phosphoramidation Reactions for Effectively Synthesizing Peptide-Oligonucleotide Conjugates Trafficked into a Human Cell Line. <i>Bioconjugate Chemistry</i> , 2012, 23, 2417-2433.	3.6	13
9	Inhibition of Hepatitis C Virus Replication by Intracellular Delivery of Multiple siRNAs by Nanosomes. <i>Molecular Therapy</i> , 2012, 20, 1724-1736.	8.2	66
10	Conjugating Phosphospermines to siRNAs for Improved Stability in Serum, Intracellular Delivery and RNAi-Mediated Gene Silencing. <i>Molecular Pharmaceutics</i> , 2012, 9, 3464-3475.	4.6	12
11	BAF60 A, B, and Cs of muscle determination and renewal. <i>Genes and Development</i> , 2012, 26, 2673-2683.	5.9	50
12	Evaluation of a microfluidics-based platform and slab electrophoresis for determination of size, integrity and quantification of in vitro transcribed RNA used as a component in therapeutic drug manufacturing. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 70, 657-663.	2.8	9
13	Creating genetic resistance to HIV. <i>Current Opinion in Immunology</i> , 2012, 24, 625-632.	5.5	39
14	Recent advances in the rational design of silica-based nanoparticles for gene therapy. <i>Therapeutic Delivery</i> , 2012, 3, 1217-1237.	2.2	36
15	Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing. <i>Chemistry and Biology</i> , 2012, 19, 937-954.	6.0	495
16	Robust Suppression of HIV Replication by Intracellularly Expressed Reverse Transcriptase Aptamers Is Independent of Ribozyme Processing. <i>Molecular Therapy</i> , 2012, 20, 2304-2314.	8.2	34
17	The highly conserved 5' untranslated region as an effective target towards the inhibition of Enterovirus 71 replication by unmodified and appropriate 2'-modified siRNAs. <i>Journal of Biomedical Science</i> , 2012, 19, 73.	7.0	22
18	Prediction of the stability of modified RNA duplexes based on deformability analysis: oligoribonucleotide derivatives modified with 2'-O-cyanoethyl-5-propynyl-2-thiouridine as a promising component. <i>Chemical Communications</i> , 2012, 48, 7313.	4.1	12

#	ARTICLE	IF	CITATIONS
19	Anti-tumor effects of an engineered "killer" transfer RNA. <i>Biochemical and Biophysical Research Communications</i> , 2012, 427, 148-153.	2.1	7
20	Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. <i>Nano Today</i> , 2012, 7, 367-379.	11.9	292
21	CHAPTER 6. Therapeutic Applications of Nucleic Acid Aptamer Conjugates. <i>RSC Biomolecular Sciences</i> , 2012, , 140-165.	0.4	0
22	Intravital Fluorescence Imaging of Small Interfering RNA-Mediated Gene Repression in a Dual Reporter Melanoma Xenograft Model. <i>Nucleic Acid Therapeutics</i> , 2012, 22, 438-443.	3.6	6
23	RNAi Joins the "Singles Club". <i>Molecular Therapy</i> , 2012, 20, 2010-2011.	8.2	2
24	Incorporation of 4'-C-aminomethyl-2'-O-methylthymidine into DNA by thermophilic DNA polymerases. <i>Chemical Communications</i> , 2012, 48, 9619.	4.1	9
25	Allele-Specific Gene Silencing in Two Mouse Models of Autosomal Dominant Skeletal Myopathy. <i>PLoS ONE</i> , 2012, 7, e49757.	2.5	17
26	Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors. <i>Biology</i> , 2012, 1, 668-697.	2.8	36
27	Current Progress of RNA Aptamer-Based Therapeutics. <i>Frontiers in Genetics</i> , 2012, 3, 234.	2.3	111
28	DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases. , 2013, , .		8
29	Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells. <i>Journal of Drug Targeting</i> , 2013, 21, 776-786.	4.4	20
30	Combinatorial targeting of 2 different steps in adenoviral DNA replication by herpes simplex virus thymidine kinase and artificial microRNA expression for the inhibition of virus multiplication in the presence of ganciclovir. <i>BMC Biotechnology</i> , 2013, 13, 54.	3.3	5
31	Cell-specific delivery of biologicals: problems, pitfalls and possibilities of antifibrotic compounds in the liver. <i>Drug Discovery Today</i> , 2013, 18, 1237-1242.	6.4	13
32	Identification of a T7 RNA polymerase variant that permits the enzymatic synthesis of fully 2'-O-methyl-modified RNA. <i>Journal of Biotechnology</i> , 2013, 167, 287-295.	3.8	39
33	Recent Advances in Ribonucleic Acid Interference (RNAi). <i>The National Academy of Sciences, India</i> , 2013, 36, 1-8.	1.3	2
34	Multifunctional Dendronized Peptide Polymer Platform for Safe and Effective siRNA Delivery. <i>Journal of the American Chemical Society</i> , 2013, 135, 4962-4965.	13.7	136
35	MicroRNAs in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1867-1875.	1.3	11
36	Gene suppression via U1 small nuclear RNA interference (U1i) machinery using oligonucleotides containing 2'-modified-4'-thionucleosides. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 5292-5296.	3.0	6

#	ARTICLE	IF	CITATIONS
37	Synthesis, RNAi activity and nuclease-resistant properties of apolar carbohydrates siRNA conjugates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4048-4051.	2.2	11
38	Near-Infrared Light-Directed RNAi Using a Photosensitive Carrier Molecule. <i>Bioconjugate Chemistry</i> , 2013, 24, 1669-1673.	3.6	14
39	Development of an Informatics Platform for Therapeutic Protein and Peptide Analytics. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 2774-2779.	5.4	10
40	Lack of detectable oral bioavailability of plant microRNAs after feeding in mice. <i>Nature Biotechnology</i> , 2013, 31, 965-967.	17.5	232
41	Technologies for Investigating the Physiological Barriers to Efficient Lipid Nanoparticle siRNA Delivery. <i>Journal of Histochemistry and Cytochemistry</i> , 2013, 61, 407-420.	2.5	21
42	Personalized Network-Based Treatments in Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 646-650.	4.7	26
44	Carbon nanotubes as vectors for gene therapy: Past achievements, present challenges and future goals. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 2023-2033.	13.7	147
45	Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery. <i>Journal of Controlled Release</i> , 2013, 171, 296-307.	9.9	87
46	Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. <i>Cancer Discovery</i> , 2013, 3, 1302-1315.	9.4	140
47	Systemic co-delivery of doxorubicin and siRNA using nanoparticles conjugated with EGFR-specific targeting peptide to enhance chemotherapy in ovarian tumor bearing mice. <i>Journal of Nanoparticle Research</i> , 2013, 15, 1.	1.9	8
48	siRNA-mediated knock-down of DFF45 amplifies doxorubicin therapeutic effects in breast cancer cells. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 515-526.	4.4	8
49	Influence of 2-Fluoro versus 2-O-Methyl Substituent on the Sugar Puckering of 4-C-Aminomethyluridine. <i>Journal of Organic Chemistry</i> , 2013, 78, 9956-9962.	3.2	23
50	De novo sequencing of short interfering ribonucleic acids facilitated by use of tandem mass spectrometry with ion mobility spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 2247-2254.	1.5	6
51	Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection. <i>Biochemical Journal</i> , 2013, 455, 133-147.	3.7	45
52	Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e91.	5.1	5
53	An adenoviral vector-based expression and delivery system for the inhibition of wild-type adenovirus replication by artificial microRNAs. <i>Antiviral Research</i> , 2013, 97, 10-23.	4.1	30
54	Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. <i>Journal of Drug Targeting</i> , 2013, 21, 27-43.	4.4	69
55	Systems-level analysis of host-pathogen interaction using RNA interference. <i>New Biotechnology</i> , 2013, 30, 308-313.	4.4	0

#	ARTICLE	IF	CITATIONS
56	Targeting eosinophils in allergy, inflammation and beyond. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 117-129.	46.4	391
57	Synthesis and properties of 2'-O-neopentyl modified oligonucleotides. <i>Organic and Biomolecular Chemistry</i> , 2013, 11, 1345.	2.8	3
58	Molecular Engineering of Guanine-Rich Sequences: Z-DNA, DNA Triplexes, and G-Quadruplexes. <i>Chemical Reviews</i> , 2013, 113, 3044-3083.	47.7	166
59	Antisense modulation of RNA processing as a therapeutic approach in cancer therapy. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2013, 10, e139-e148.	0.5	9
60	Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery. <i>International Journal of Pharmaceutics</i> , 2013, 455, 40-47.	5.2	49
61	High-throughput purification of double-stranded RNA molecules using convective interaction media monolithic anion exchange columns. <i>Journal of Chromatography A</i> , 2013, 1278, 54-60.	3.7	42
62	Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 290.	4.8	3
63	A Fabricated siRNA Nanoparticle for Ultralong Gene Silencing In Vivo. <i>Advanced Functional Materials</i> , 2013, 23, 3488-3493.	14.9	21
64	Silencing human genetic diseases with oligonucleotide-based therapies. <i>Human Genetics</i> , 2013, 132, 481-493.	3.8	49
65	Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART. <i>Gene Therapy</i> , 2013, 20, 695-702.	4.5	35
66	Advances with RNA interference in Alzheimer's disease research. <i>Drug Design, Development and Therapy</i> , 2013, 7, 117.	4.3	20
67	Protein-resistant, reductively dissociable polyplexes for in vivo systemic delivery and tumor-targeting of siRNA. <i>Biomaterials</i> , 2013, 34, 2370-2379.	11.4	46
68	Gene Silencing via RNAi and siRNA Quantification in Tumor Tissue Using MEND, a Liposomal siRNA Delivery System. <i>Molecular Therapy</i> , 2013, 21, 1195-1203.	8.2	112
69	Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. <i>Molecular Oncology</i> , 2013, 7, 580-594.	4.6	80
70	Aberrant microRNA expression in multiple myeloma. <i>European Journal of Haematology</i> , 2013, 91, 95-105.	2.2	40
71	Acidic pH-Responsive siRNA Conjugate for Reversible Carrier Stability and Accelerated Endosomal Escape with Reduced IFN- γ -Associated Immune Response. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 6218-6221.	13.8	103
72	Nanolayered siRNA Dressing for Sustained Localized Knockdown. <i>ACS Nano</i> , 2013, 7, 5251-5261.	14.6	45
73	Design and synthesis of a nucleoside and a phosphonate analogue constructed on a branched-threo-tetrofuranose skeleton. <i>Tetrahedron Letters</i> , 2013, 54, 3949-3952.	1.4	9

#	ARTICLE	IF	CITATIONS
74	siRNA-Chitosan Complexes in Poly(lactic-co-glycolic acid) Nanoparticles for the Silencing of Aquaporin-1 in Cancer Cells. <i>Molecular Pharmaceutics</i> , 2013, 10, 3186-3194.	4.6	22
75	Adenovirus vector-mediated RNA interference for the inhibition of human parvovirus B19 replication. <i>Virus Research</i> , 2013, 176, 155-160.	2.2	8
76	Current Challenges in Nucleic Acid Synthesis. <i>Israel Journal of Chemistry</i> , 2013, 53, 326-349.	2.3	15
77	Matrix Metalloproteinase Responsive, Proximity-Activated Polymeric Nanoparticles for siRNA Delivery. <i>Advanced Functional Materials</i> , 2013, 23, 3040-3052.	14.9	100
78	Recent developments in human immunodeficiency virus-1 latency research. <i>Journal of General Virology</i> , 2013, 94, 917-932.	2.9	17
79	Covalent conjugation of oligonucleotides with cell-targeting ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6217-6223.	3.0	17
80	Silica nanogelling of environment-responsive PEGylated polyplexes for enhanced stability and intracellular delivery of siRNA. <i>Biomaterials</i> , 2013, 34, 562-570.	11.4	29
81	Effects of Hypoxanthine Substitution in Peptide Nucleic Acids Targeting <i>KRAS2</i> Oncogenic mRNA Molecules: Theory and Experiment. <i>Journal of Physical Chemistry B</i> , 2013, 117, 11584-11595.	2.6	25
82	Structure and Conformational Dynamics of the Domain 5 RNA Hairpin of a Bacterial Group II Intron Revealed by Solution Nuclear Magnetic Resonance and Molecular Dynamics Simulations. <i>Biochemistry</i> , 2013, 52, 7099-7113.	2.5	10
83	Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery. <i>Circulation Research</i> , 2013, 112, 534-548.	4.5	99
84	Computational Approaches to Predicting the Impact of Novel Bases on RNA Structure and Stability. <i>ACS Chemical Biology</i> , 2013, 8, 2354-2359.	3.4	7
85	Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity. <i>Nucleic Acids Research</i> , 2013, 41, 4650-4659.	14.5	13
86	Gene Therapy Strategies for HIV/AIDS: Preclinical Modeling in Humanized Mice. <i>Viruses</i> , 2013, 5, 3119-3141.	3.3	11
87	Regulatory RNAs. <i>RNA Biology</i> , 2013, 10, 1778-1797.	3.1	50
88	DNA Duplexes with Hydrophobic Modifications Inhibit Fusion between HIV-1 and Cell Membranes. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4963-4970.	3.2	9
89	Oligonucleotide conjugates for therapeutic applications. <i>Therapeutic Delivery</i> , 2013, 4, 791-809.	2.2	117
90	Design of siRNA Therapeutics from the Molecular Scale. <i>Pharmaceutics</i> , 2013, 6, 440-468.	3.8	33
91	Aptamer-Based Therapeutics: New Approaches to Combat Human Viral Diseases. <i>Pharmaceutics</i> , 2013, 6, 1507-1542.	3.8	58

#	ARTICLE	IF	CITATIONS
92	Prospects for nucleic acid-based therapeutics against hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2013, 19, 8949.	3.3	13
93	Current progress on aptamer-targeted oligonucleotide therapeutics. <i>Therapeutic Delivery</i> , 2013, 4, 1527-1546.	2.2	90
94	Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. <i>Pharmaceuticals</i> , 2013, 6, 85-107.	3.8	171
95	Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers. <i>Pharmaceuticals</i> , 2013, 6, 295-319.	3.8	30
96	Contribution of Long Noncoding RNAs to Autism Spectrum Disorder Risk. <i>International Review of Neurobiology</i> , 2013, 113, 35-59.	2.0	39
97	Gene Silencing in Skin After Deposition of Self-Delivery siRNA With a Motorized Microneedle Array Device. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e129.	5.1	25
98	A novel platform to enable inhaled naked RNAi medicine for lung cancer. <i>Scientific Reports</i> , 2013, 3, 3325.	3.3	44
99	Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. <i>Journal of Cancer Therapy</i> , 2013, 04, 872-890.	0.4	18
101	Challenges in the Chemistry of Small Interfering RNA as Potential Therapeutics to Inhibit Cellular mRNA Expression. , 2013, , .		0
102	Suppression of Gq Function Using Intra-Pipette Delivery of shRNA during Extracellular Recording in the Ventral Tegmental Area. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 7.	3.7	6
103	siRNA Treatment: "A Sword-in-the-Stone" for Acute Brain Injuries. <i>Genes</i> , 2013, 4, 435-456.	2.4	21
104	Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice. <i>PLoS ONE</i> , 2014, 9, e109970.	2.5	17
105	Biologics: the role of delivery systems in improved therapy. <i>Biologics: Targets and Therapy</i> , 2014, 8, 107.	3.2	63
106	Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity. <i>International Journal of Nanomedicine</i> , 2014, 9, 2271.	6.7	16
107	Cancer-targeting siRNA delivery from porous silicon nanoparticles. <i>Nanomedicine</i> , 2014, 9, 2309-2321.	3.3	26
109	New perspectives on the use of nucleic acids in pharmacological applications: inhibitory action of extracellular self-DNA in biological systems. <i>Phytochemistry Reviews</i> , 2014, 13, 937-946.	6.5	13
110	Co-transcriptional production of RNA-DNA hybrids for simultaneous release of multiple split functionalities. <i>Nucleic Acids Research</i> , 2014, 42, 2085-2097.	14.5	54
111	Direct Synthesis of Partially Modified 2'-O-Methyl RNAs by a Base-Labile Protecting Group Strategy and their Potential for Prodrug-Based Gene Silencing Applications. <i>ChemBioChem</i> , 2014, 15, 2674-2679.	2.6	11

#	ARTICLE	IF	CITATIONS
112	Future nanomedicine for the diagnosis and treatment of osteoarthritis. <i>Nanomedicine</i> , 2014, 9, 2203-2215.	3.3	21
113	Sequence-defined polymers for the delivery of oligonucleotides. <i>Nanomedicine</i> , 2014, 9, 2843-2859.	3.3	16
114	Gene Delivery into Cells and Tissues. , 2014, , 687-723.		2
115	Targeted siRNA therapy using cytoplasm-responsive nanocarriers and cell-penetrating peptides. <i>Journal of Pharmaceutical Investigation</i> , 2014, 44, 505-516.	5.3	3
116	A Conserved Target Site in HIV-1 Gag RNA is Accessible to Inhibition by Both an HDV Ribozyme and a Short Hairpin RNA. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e178.	5.1	16
117	Emerging techniques employed in aptamer-based diagnostic tests. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 143-151.	3.1	16
118	siRNA-mediated Allele-specific Silencing of a COL6A3 Mutation in a Cellular Model of Dominant Ullrich Muscular Dystrophy. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e147.	5.1	25
119	Cytoplasm-Responsive Delivery Systems for siRNA Using Cell-Penetrating Peptide Nanomicelles. <i>Journal of Drug Delivery Science and Technology</i> , 2014, 24, 3-11.	3.0	12
120	Sequence motifs associated with hepatotoxicity of locked nucleic acid [®] modified antisense oligonucleotides. <i>Nucleic Acids Research</i> , 2014, 42, 4882-4891.	14.5	129
121	A U87-EGFRvIII cell-specific aptamer mediates small interfering RNA delivery. <i>Biomedical Reports</i> , 2014, 2, 495-499.	2.0	22
122	An orthogonal photolabile linker for the complete ³ on-support ⁴ synthesis/fast deprotection/hybridization of RNA. <i>Chemical Communications</i> , 2014, 50, 15063-15066.	4.1	6
123	4: GENETIC PHARMACOLOGY USING SYNTHETIC DEOXYRIBONUCLEOTIDES. <i>ICP Textbooks in Biomolecular Sciences</i> , 2014, , 31-52.	0.1	0
124	Delivery of Therapeutic siRNA to the Lung Endothelium via Novel Lipoplex Formulation DACC. <i>Molecular Therapy</i> , 2014, 22, 811-820.	8.2	84
125	Smad3: An emerging target for vocal fold fibrosis. <i>Laryngoscope</i> , 2014, 124, 2327-2331.	2.0	21
127	Challenges posed to the European pharmaceutical regulatory system by highly personalized medicines. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 421-426.	2.4	3
128	Synthesis of multi-galactose-conjugated 2 [®] -O-methyl oligoribonucleotides and their in vivo imaging with positron emission tomography. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6806-6813.	3.0	16
129	Site [®] Directed RNA Editing with Antagomir Deaminases [®] A Tool to Study Protein and RNA Function. <i>ChemMedChem</i> , 2014, 9, 2021-2025.	3.2	33
130	Fine [®] Tuning of Charge [®] Conversion Polymer Structure for Efficient Endosomal Escape of siRNA [®] Loaded Calcium Phosphate Hybrid Micelles. <i>Macromolecular Rapid Communications</i> , 2014, 35, 1211-1215.	3.9	44

#	ARTICLE	IF	CITATIONS
131	A promising gene delivery system developed from PEGylated MoS ₂ nanosheets for gene therapy. <i>Nanoscale Research Letters</i> , 2014, 9, 587.	5.7	77
133	Cell-penetrating peptide polymer nanomicelle-based cytosol-sensitive nucleotide delivery systems. , 2014, , 347-368.		0
134	In vivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation. <i>Journal of Controlled Release</i> , 2014, 196, 355-362.	9.9	34
135	Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA. <i>Nucleic Acids Research</i> , 2014, 42, 11805-11817.	14.5	67
136	Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?. <i>Neurodegenerative Disease Management</i> , 2014, 4, 417-437.	2.2	13
137	Chemically Modified DNA Aptamers Bind Interleukin-6 with High Affinity and Inhibit Signaling by Blocking Its Interaction with Interleukin-6 Receptor. <i>Journal of Biological Chemistry</i> , 2014, 289, 8706-8719.	3.4	128
138	CD19CAR T Cells. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 107-111.	2.0	3
139	A Small Molecule Screen Identifies an Inhibitor of DNA Repair Inducing the Degradation of TFIIH and the Chemosensitization of Tumor Cells to Platinum. <i>Chemistry and Biology</i> , 2014, 21, 398-407.	6.0	72
140	Functional Deregulation of KIT. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 219-237.	1.9	81
141	Systemic siRNA delivery to a spontaneous pancreatic tumor model in transgenic mice by PEGylated calcium phosphate hybrid micelles. <i>Journal of Controlled Release</i> , 2014, 178, 18-24.	9.9	108
142	Exosomes: Mediators of Neurodegeneration, Neuroprotection and Therapeutics. <i>Molecular Neurobiology</i> , 2014, 49, 590-600.	4.0	281
143	Preclinical development of siRNA therapeutics: Towards the match between fundamental science and engineered systems. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 689-702.	3.3	48
145	Therapeutic Applications of Ribozymes and Riboswitches. <i>Methods in Molecular Biology</i> , 2014, , .	0.9	0
146	Practical Considerations in Gene Therapy for HIV Cure. <i>Current HIV/AIDS Reports</i> , 2014, 11, 11-19.	3.1	21
147	Multifunctional polyion complex micelle featuring enhanced stability, targetability, and endosome escapability for systemic siRNA delivery to subcutaneous model of lung cancer. <i>Drug Delivery and Translational Research</i> , 2014, 4, 50-60.	5.8	43
148	Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases. <i>Drug Discovery Today</i> , 2014, 19, 1309-1321.	6.4	33
149	Targeting kallikrein-related peptidases in prostate cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 365-383.	3.4	25
150	Pyrazolo[1,5- <i>c</i>]-1,3,5-triazine C-Nucleoside as Deoxyadenosine Analogue: Synthesis, Pairing, and Resistance to Hydrolysis. <i>Journal of Organic Chemistry</i> , 2014, 79, 3221-3227.	3.2	14

#	ARTICLE	IF	CITATIONS
151	Inhibition of Receptor Signaling and of Glioblastoma-derived Tumor Growth by a Novel PDGFR β Aptamer. <i>Molecular Therapy</i> , 2014, 22, 828-841.	8.2	118
152	Modeling of Antigenomic Therapy of Mitochondrial Diseases by Mitochondrially Addressed RNA Targeting a Pathogenic Point Mutation in Mitochondrial DNA. <i>Journal of Biological Chemistry</i> , 2014, 289, 13323-13334.	3.4	39
154	Diversity, evolution, and therapeutic applications of small RNAs in prokaryotic and eukaryotic immune systems. <i>Physics of Life Reviews</i> , 2014, 11, 113-134.	2.8	16
155	Bacterial Delivery of RNAi Effectors. , 2014, , 67-75.		1
156	Characterization of chemically modified oligonucleotides targeting a pathogenic mutation in human mitochondrial DNA. <i>Biochimie</i> , 2014, 100, 192-199.	2.6	17
157	Liposomal siRNA nanocarriers for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2014, 66, 110-116.	13.7	364
158	Viral vectors expressing a single microRNA-based short-hairpin RNA result in potent gene silencing in vitro and in vivo. <i>Journal of Biotechnology</i> , 2014, 169, 71-81.	3.8	22
159	Dissecting the Effect of RNA Aptamer Binding on the Dynamics of Plasminogen Activator Inhibitor 1 Using Hydrogen/Deuterium Exchange Mass Spectrometry. <i>ACS Chemical Biology</i> , 2014, 9, 174-182.	3.4	32
160	Lipopolyplexes comprising imidazole/imidazolium lipophosphoramidate, histidinylated polyethyleneimine and siRNA as efficient formulation for siRNA transfection. <i>International Journal of Pharmaceutics</i> , 2014, 460, 264-272.	5.2	44
161	Nucleic Acid Nanotechnology. <i>Nucleic Acids and Molecular Biology</i> , 2014, , .	0.2	5
162	Aptamers in immunological research. <i>Immunology Letters</i> , 2014, 162, 252-255.	2.5	24
163	Improved nuclear delivery of antisense 2'-Ome RNA by conjugation with the histidine-rich peptide H5WYG. <i>Journal of Gene Medicine</i> , 2014, 16, 157-165.	2.8	10
164	Discovery of siRNA Lipid Nanoparticles to Transfect Suspension Leukemia Cells and Provide In Vivo Delivery Capability. <i>Molecular Therapy</i> , 2014, 22, 359-370.	8.2	53
165	Organ-targeted high-throughput in vivo biologics screen identifies materials for RNA delivery. <i>Integrative Biology (United Kingdom)</i> , 2014, 6, 926-934.	1.3	26
166	Precise Engineering of siRNA Delivery Vehicles to Tumors Using Polyion Complexes and Gold Nanoparticles. <i>ACS Nano</i> , 2014, 8, 8979-8991.	14.6	126
167	Matrix metalloproteinase 2-responsive micelle for siRNA delivery. <i>Biomaterials</i> , 2014, 35, 7622-7634.	11.4	102
168	Folic acid conjugated chitosan for targeted delivery of siRNA to activated macrophages in vitro and in vivo. <i>Journal of Materials Chemistry B</i> , 2014, 2, 8608-8615.	5.8	69
169	Antisense oligonucleotides: modifications and clinical trials. <i>MedChemComm</i> , 2014, 5, 1454-1471.	3.4	165

#	ARTICLE	IF	CITATIONS
170	An Aptamer Intrinsically Comprising 5-Fluoro-2-Deoxyuridine for Targeted Chemotherapy. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 10541-10544.	13.8	49
171	Dilution-Stable PAMAM G1-Grafted Polyrotaxane Supermolecules Deliver Gene into Cells through a Caveolae-Dependent Pathway. <i>Molecular Pharmaceutics</i> , 2014, 11, 2323-2333.	4.6	21
172	Vector platforms for gene therapy of inherited retinopathies. <i>Progress in Retinal and Eye Research</i> , 2014, 43, 108-128.	15.5	146
173	Cellular Uptake and Intracellular Trafficking of Oligonucleotides: Implications for Oligonucleotide Pharmacology. <i>Nucleic Acid Therapeutics</i> , 2014, 24, 101-113.	3.6	99
174	Actively-targeted polyion complex micelles stabilized by cholesterol and disulfide cross-linking for systemic delivery of siRNA to solid tumors. <i>Biomaterials</i> , 2014, 35, 7887-7895.	11.4	113
175	Conjugation with Receptor-Targeted Histidine-Rich Peptides Enhances the Pharmacological Effectiveness of Antisense Oligonucleotides. <i>Bioconjugate Chemistry</i> , 2014, 25, 165-170.	3.6	21
176	Targeting strategies for delivery of anti-HIV drugs. <i>Journal of Controlled Release</i> , 2014, 192, 271-283.	9.9	47
177	Advances in self-assembled chitosan nanomaterials for drug delivery. <i>Biotechnology Advances</i> , 2014, 32, 1301-1316.	11.7	260
178	Emerging approaches to target tumor metabolism. <i>Current Opinion in Pharmacology</i> , 2014, 17, 22-29.	3.5	18
179	Aptamers as Drug Delivery Vehicles. <i>ChemMedChem</i> , 2014, 9, 1998-2011.	3.2	50
180	Periodical assembly of repetitive RNA sequences synthesized by rolling circle transcription with short DNA staple strands to RNA-DNA hybrid nanowires. <i>Chemical Communications</i> , 2014, 50, 2100.	4.1	13
181	Mad2 Checkpoint Gene Silencing Using Epidermal Growth Factor Receptor-Targeted Chitosan Nanoparticles in Non-Small Cell Lung Cancer Model. <i>Molecular Pharmaceutics</i> , 2014, 11, 3515-3527.	4.6	55
182	Towards improved shRNA and miRNA reagents as inhibitors of HIV1 replication. <i>Future Microbiology</i> , 2014, 9, 561-571.	2.0	24
183	Properties of 5- and/or 2-modified 2-O-cyanoethyl uridine residue: 2-O-cyanoethyl-5-propynyl-2-thiouridine as an efficient duplex stabilizing component. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 1157.	2.8	3
184	Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 1517-1527.	3.3	242
185	MicroRNAs in Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 203-214.	3.9	96
186	A 3'UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1. <i>Molecular Cancer</i> , 2014, 13, 87.	19.2	31
187	siRNA: novel therapeutics from functional genomics. <i>Biotechnology and Genetic Engineering Reviews</i> , 2014, 30, 1-30.	6.2	11

#	ARTICLE	IF	CITATIONS
188	Development of RNA Interference-Based Therapeutics and Application of Multi-Target Small Interfering RNAs. <i>Nucleic Acid Therapeutics</i> , 2014, 24, 302-312.	3.6	22
189	Bifunctional pH-sensitive Zn(II)-curcumin nanoparticles/siRNA effectively inhibit growth of human bladder cancer cells in vitro and in vivo. <i>Journal of Materials Chemistry B</i> , 2014, 2, 2714.	5.8	21
190	High-performance liquid chromatography purification of chemically modified RNA aptamers. <i>Analytical Biochemistry</i> , 2014, 449, 106-108.	2.4	9
191	Ribonucleic acid purification. <i>Journal of Chromatography A</i> , 2014, 1355, 1-14.	3.7	54
192	<i>In Silico</i> Design and Enzymatic Synthesis of Functional RNA Nanoparticles. <i>Accounts of Chemical Research</i> , 2014, 47, 1731-1741.	15.6	80
193	Non-viral nanocarriers for siRNA delivery in breast cancer. <i>Journal of Controlled Release</i> , 2014, 190, 440-450.	9.9	75
194	Implementation of Nanoparticles in Cancer Therapy. <i>Advances in Chemical and Materials Engineering Book Series</i> , 2014, , 447-491.	0.3	5
195	Lung-Targeted RNA Interference Against Angiopoietin-2 Ameliorates Multiple Organ Dysfunction and Death in Sepsis. <i>Critical Care Medicine</i> , 2014, 42, e654-e662.	0.9	61
196	Knocking down the expression of Aurora-A gene inhibits cell proliferation and induces G2/M phase arrest in human small cell lung cancer cells. <i>Oncology Reports</i> , 2014, 32, 243-249.	2.6	32
197	Liquid-Phase Synthesis of 2-Methyl RNA on a Homostar Support through Organic Solvent Nanofiltration. <i>Chemistry - A European Journal</i> , 2015, 21, 9535-9543.	3.3	17
198	Fluorescence Imaging of siRNA Delivery by Peptide Nucleic Acid-based Probe. <i>Analytical Sciences</i> , 2015, 31, 315-320.	1.6	15
200	Targeting mitosis-regulating genes in cisplatin-sensitive and -resistant melanoma cells: A live-cell RNAi screen displays differential nucleus-derived phenotypes. <i>Biotechnology Journal</i> , 2015, 10, 1467-1477.	3.5	3
201	Supramolecular Assembly Models of siRNA Delivery Systems. <i>Chinese Journal of Chemistry</i> , 2015, 33, 79-89.	4.9	9
202	Preparation of a disulfide-linked precipitative soluble support for solution-phase synthesis of trimeric oligodeoxyribonucleotide 3'-((2-chlorophenyl)phosphate) building blocks. <i>Beilstein Journal of Organic Chemistry</i> , 2015, 11, 1553-1560.	2.2	9
203	Fitness Landscapes of Functional RNAs. <i>Life</i> , 2015, 5, 1497-1517.	2.4	11
204	Mitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 19836-19850.	4.1	23
205	Modulation of the RNA Interference Activity Using Central Mismatched siRNAs and Acyclic Threoninol Nucleic Acids (aTNA) Units. <i>Molecules</i> , 2015, 20, 7602-7619.	3.8	15
206	HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET. <i>Current Drug Targets</i> , 2015, 17, 33-45.	2.1	19

#	ARTICLE	IF	CITATIONS
207	Targeting Th17 Cells with Small Molecules and Small Interference RNA. Mediators of Inflammation, 2015, 2015, 1-11.	3.0	15
208	Novel Prospective Treatment Options. , 2015, , .		1
209	MicroRNAs as master regulators of immune responses in transplant recipients. Current Opinion in Organ Transplantation, 2015, 20, 29-36.	1.6	19
210	Therapeutic Applications of Spherical Nucleic Acids. Cancer Treatment and Research, 2015, 166, 23-50.	0.5	32
211	Incorporation of an acyclic alkynyl nucleoside analog into siRNA improves silencing activity and nuclease resistance. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2574-2578.	2.2	3
212	Development of Small RNA Delivery Systems for Lung Cancer Therapy. International Journal of Molecular Sciences, 2015, 16, 5254-5270.	4.1	57
213	Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nature Reviews Drug Discovery, 2015, 14, 843-856.	46.4	349
214	Inhibition of HIV-1 gp41 expression with hammerhead ribozymes. Biochemical Journal, 2015, 471, 53-66.	3.7	4
215	Preclinical and clinical development of siRNA-based therapeutics. Advanced Drug Delivery Reviews, 2015, 87, 108-119.	13.7	382
217	Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics. Journal of Controlled Release, 2015, 203, 1-15.	9.9	240
218	RNA aptamers as genetic control devices: The potential of riboswitches as synthetic elements for regulating gene expression. Biotechnology Journal, 2015, 10, 246-257.	3.5	91
219	Screening Nylon-3 Polymers, a New Class of Cationic Amphiphiles, for siRNA Delivery. Molecular Pharmaceutics, 2015, 12, 362-374.	4.6	25
220	Carbon nanotubes part II: a remarkable carrier for drug and gene delivery. Expert Opinion on Drug Delivery, 2015, 12, 1089-1105.	5.0	145
221	Peptide Nanofiber Complexes with siRNA for Deep Brain Gene Silencing by Stereotactic Neurosurgery. ACS Nano, 2015, 9, 1137-1149.	14.6	41
222	Noncoding Oligonucleotides: The Belle of the Ball in Gene Therapy. Advances in Genetics, 2015, 89, 153-177.	1.8	4
223	Synthetic biology devices and circuits for RNA-based "smart vaccines": a propositional review. Expert Review of Vaccines, 2015, 14, 313-331.	4.4	33
224	Gene- and Cell-Based Treatment Strategies for the Eye. Essentials in Ophthalmology, 2015, , .	0.1	2
225	Tenascin-C: Exploitation and collateral damage in cancer management. Cell Adhesion and Migration, 2015, 9, 141-153.	2.7	54

#	ARTICLE	IF	CITATIONS
226	Aptamer Selection Technology and Recent Advances. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e223.	5.1	250
227	miRNAs in Bone Repair. , 2015, , 653-683.		2
228	MicroRNAs in Normal and Malignant Myelopoiesis. , 2015, , 213-236.		0
229	Targeting HIV Transcription: The Quest for a Functional Cure. <i>Current Topics in Microbiology and Immunology</i> , 2015, 389, 121-145.	1.1	66
230	Synthesis and Properties of 2'-Deoxy-2',4'-difluoroarabinose-Modified Nucleic Acids. <i>Journal of Organic Chemistry</i> , 2015, 80, 3083-3091.	3.2	32
231	High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides. <i>Nucleic Acids Research</i> , 2015, 43, 1987-1996.	14.5	73
232	RNA-targeted Therapeutics for ALS. <i>Neurotherapeutics</i> , 2015, 12, 424-427.	4.4	20
233	Sensorimotor Cortex Injection of Adeno-Associated Viral Vector Mediates Knockout of PTEN in Neurons of the Brain and Spinal Cord of Mice. <i>Journal of Molecular Neuroscience</i> , 2015, 57, 470-476.	2.3	5
234	Synthesis, binding, nuclease resistance and cellular uptake properties of 2'-O -acetalester-modified oligonucleotides containing cationic groups. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5360-5368.	3.0	9
235	Oligonucleotide Therapies: The Past and the Present. <i>Human Gene Therapy</i> , 2015, 26, 475-485.	2.7	220
236	Long non-coding RNA and chromatin remodeling. <i>RNA Biology</i> , 2015, 12, 1094-1098.	3.1	185
237	Selective Small Molecule Compounds Increase BMP-2 Responsiveness by Inhibiting Smurf1-mediated Smad1/5 Degradation. <i>Scientific Reports</i> , 2014, 4, 4965.	3.3	63
238	Redox-Sensitive PEG-Polypeptide Nanoporous Particles for Survivin Silencing in Prostate Cancer Cells. <i>Biomacromolecules</i> , 2015, 16, 2168-2178.	5.4	38
239	Synthetic Polymer Hybridization with DNA and RNA Directs Nanoparticle Loading, Silencing Delivery, and Aptamer Function. <i>Journal of the American Chemical Society</i> , 2015, 137, 8920-8923.	13.7	26
240	A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. <i>Nucleic Acids Research</i> , 2015, 43, 3857-3869.	14.5	64
241	Oligonucleotide-Based Drug Development: Considerations for Clinical Pharmacology and Immunogenicity. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 861-868.	1.6	11
242	Nanoparticle delivery of stable miR-199a-5p agomir improves the osteogenesis of human mesenchymal stem cells via the HIF1a pathway. <i>Biomaterials</i> , 2015, 53, 239-250.	11.4	113
243	Peptidic tools applied to redirect alternative splicing events. <i>Peptides</i> , 2015, 67, 1-11.	2.4	4

#	ARTICLE	IF	CITATIONS
244	Oligonucleotide inhibitors of telomerase: Prospects for anticancer therapy and diagnostics. <i>Biochemistry (Moscow)</i> , 2015, 80, 251-259.	1.5	9
245	A Universal Aptamer Chimera for the Delivery of Functional microRNA-126. <i>Nucleic Acid Therapeutics</i> , 2015, 25, 141-151.	3.6	40
246	HIV and Ribozymes. <i>Advances in Experimental Medicine and Biology</i> , 2015, 848, 97-116.	1.6	25
247	Personalizing Biomaterials for Precision Nanomedicine Considering the Local Tissue Microenvironment. <i>Advanced Healthcare Materials</i> , 2015, 4, 1584-1599.	7.6	44
248	Pruning of biomolecules and natural products (PBNP): an innovative paradigm in drug discovery. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 6432-6448.	2.8	17
249	Gene Therapy for Dominantly Inherited Retinal Degeneration. <i>Essentials in Ophthalmology</i> , 2015, , 43-60.	0.1	1
250	RNA Nanotechnology and Therapeutics. <i>Methods in Molecular Biology</i> , 2015, , .	0.9	3
251	Live cell imaging of duplex siRNA intracellular trafficking. <i>Nucleic Acids Research</i> , 2015, 43, 4650-4660.	14.5	53
252	Mitochondrial Targeting of Recombinant RNA. <i>Methods in Molecular Biology</i> , 2015, 1265, 209-225.	0.9	13
253	An Update on MicroRNA's and Metabolic Regulation with Future Therapeutic Potentials Regarding Diagnosis and Treatment of Obesity, Metabolic Syndrome and Other Related Disorders. <i>Journal of Health & Medical Informatics</i> , 2015, 06, .	0.2	2
254	Designing optogenetically controlled RNA for regulating biological systems. <i>Annals of the New York Academy of Sciences</i> , 2015, 1352, 13-19.	3.8	15
255	Mitochondrial Medicine. <i>Methods in Molecular Biology</i> , 2015, , .	0.9	4
256	Evaluation of dendrimer type bio-reducible polymer as a siRNA delivery carrier for cancer therapy. <i>Journal of Controlled Release</i> , 2015, 209, 179-185.	9.9	39
257	Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer. <i>Cancer Treatment and Research</i> , 2015, , .	0.5	25
258	Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. <i>Nucleic Acids Research</i> , 2015, 43, 3407-3419.	14.5	124
261	Gene Therapy Strategies to Block HIV-1 Replication by RNA Interference. <i>Advances in Experimental Medicine and Biology</i> , 2015, 848, 71-95.	1.6	12
262	Silica nanowire conjugated with loop-shaped oligonucleotides: A new structure to silence cysteine proteinase gene in <i>Leishmania tropica</i> . <i>Colloids and Surfaces B: Biointerfaces</i> , 2015, 136, 323-328.	5.0	4
263	Directed evolution of artificial enzymes (XNAzymes) from diverse repertoires of synthetic genetic polymers. <i>Nature Protocols</i> , 2015, 10, 1625-1642.	12.0	40

#	ARTICLE	IF	CITATIONS
264	15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics. <i>Nano Today</i> , 2015, 10, 421-450.	11.9	73
265	Heat Shock Protein-Based Therapies. <i>Heat Shock Proteins</i> , 2015, , .	0.2	5
266	Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2279-2291.	4.1	66
267	Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. <i>Nucleic Acids Research</i> , 2015, 43, 3318-3331.	14.5	78
268	Ribozyme-Spherical Nucleic Acids. <i>Journal of the American Chemical Society</i> , 2015, 137, 10528-10531.	13.7	58
269	Therapeutic oligonucleotides with polyethylene glycol modifications. <i>Future Medicinal Chemistry</i> , 2015, 7, 1721-1731.	2.3	24
270	Polyamine-oligonucleotide conjugates: a promising direction for nucleic acid tools and therapeutics. <i>Future Medicinal Chemistry</i> , 2015, 7, 1733-1749.	2.3	11
271	Manipulating the in vivo immune response by targeted gene knockdown. <i>Current Opinion in Immunology</i> , 2015, 35, 63-72.	5.5	7
272	Concise postsynthetic preparation of oligonucleotide-oligopeptide conjugates through facile disulfide bond formation. <i>Future Medicinal Chemistry</i> , 2015, 7, 1657-1673.	2.3	10
273	Synthetic CRISPR RNA-Cas9-guided genome editing in human cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E7110-7.	7.1	151
274	Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder. <i>Current Topics in Microbiology and Immunology</i> , 2015, 389, 147-169.	1.1	29
275	Effective Inhibition of HIV-1 Production by Short Hairpin RNAs and Small Interfering RNAs Targeting a Highly Conserved Site in HIV-1 Gag RNA Is Optimized by Evaluating Alternative Length Formats. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5297-5305.	3.2	13
276	Synthetic fluorescent probes capable of selective recognition of 3'-overhanging nucleotides for siRNA delivery imaging. <i>Chemical Communications</i> , 2015, 51, 1421-1424.	4.1	17
277	Focusing on long noncoding RNA dysregulation in gastric cancer. <i>Tumor Biology</i> , 2015, 36, 129-141.	1.8	26
278	Software for predicting the 3D structure of RNA molecules. <i>Wiley Interdisciplinary Reviews: Computational Molecular Science</i> , 2015, 5, 56-61.	14.6	5
279	Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer. <i>Biotechnology Advances</i> , 2015, 33, 224-241.	11.7	35
280	Regulatory Non-Coding RNAs. <i>Methods in Molecular Biology</i> , 2015, , .	0.9	2
281	Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 469-503.	5.4	30

#	ARTICLE	IF	CITATIONS
282	Breast anticancer drug tamoxifen and its metabolites bind tRNA at multiple sites. <i>International Journal of Biological Macromolecules</i> , 2015, 72, 692-698.	7.5	9
283	The Eternal Fight against Cancer. <i>Journal of Medical Toxicology and Clinical Forensic Medicine</i> , 2016, 2, .	0.2	0
284	Smart polymeric nanocarriers for small nucleic acid delivery. <i>Drug Discoveries and Therapeutics</i> , 2016, 10, 236-247.	1.5	13
285	Inherited Defects and Gene Therapy. , 2016, , 523-564.		1
286	RNAi-based Gene Therapy for Blood Genetic Diseases. , 2016, , .		1
287	Tamoxifen Resistance: Emerging Molecular Targets. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1357.	4.1	92
288	An Adaptive Defect Weighted Sampling Algorithm to Design Pseudoknotted RNA Secondary Structures. <i>Frontiers in Genetics</i> , 2016, 7, 129.	2.3	3
289	In vitro repair of a defective EGFP transcript and translation into a functional protein. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 6729-6737.	2.8	6
290	Dextran functionalization enhances nanoparticle-mediated siRNA delivery and silencing. <i>Technology</i> , 2016, 04, 42-54.	1.4	13
291	The role of <i>Scp</i> mad3 in the fibrotic phenotype in human vocal fold fibroblasts. <i>Laryngoscope</i> , 2016, 126, 1151-1156.	2.0	26
292	<i>scp</i> siRNA and <i>scp</i> RNAi optimization. <i>Wiley Interdisciplinary Reviews RNA</i> , 2016, 7, 316-329.	6.4	67
293	Reductive Decationizable Block Copolymers for Stimuli-Responsive mRNA Delivery. <i>Macromolecular Rapid Communications</i> , 2016, 37, 924-933.	3.9	36
294	Characterization of nucleic acids by tandem mass spectrometry •The second decade (2004–2013): From DNA to RNA and modified sequences. <i>Mass Spectrometry Reviews</i> , 2016, 35, 483-523.	5.4	56
295	Bioengineering of noncoding <i>scp</i> RNAs for research agents and therapeutics. <i>Wiley Interdisciplinary Reviews RNA</i> , 2016, 7, 186-197.	6.4	57
297	Suppression of the Eag1 potassium channel sensitizes glioblastoma cells to injury caused by temozolomide. <i>Oncology Letters</i> , 2016, 12, 2581-2589.	1.8	32
298	Gram-scale Chemical Synthesis of Base-Modified Ribonucleoside-5'-O-Triphosphates. <i>Current Protocols in Nucleic Acid Chemistry</i> , 2016, 67, 13.15.1-13.15.10.	0.5	1
300	Method of carrier-free delivery of therapeutic RNA importable into human mitochondria: Lipophilic conjugates with cleavable bonds. <i>Biomaterials</i> , 2016, 76, 408-417.	11.4	32
301	Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. <i>Cancer Treatment Reviews</i> , 2016, 45, 19-29.	7.7	21

#	ARTICLE	IF	CITATIONS
302	The delivery of therapeutic oligonucleotides. <i>Nucleic Acids Research</i> , 2016, 44, 6518-6548.	14.5	656
303	Evaluating TNA stability under simulated physiological conditions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2418-2421.	2.2	66
304	A Novel p19 Fusion Protein as a Delivery Agent for Short-interfering RNAs. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e303.	5.1	12
305	Antisense molecules: A new class of drugs. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1334-1346.	2.9	56
306	An Efficient Protection-Free One-Pot Chemical Synthesis of Modified Nucleoside-5'-Triphosphates. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2016, 35, 356-362.	1.1	15
307	Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy. <i>Toxicologic Pathology</i> , 2016, 44, 856-865.	1.8	54
308	RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. <i>Cancer Treatment Reviews</i> , 2016, 50, 35-47.	7.7	128
309	The Evolving Role of the Medicinal Chemist. <i>Progress in Medicinal Chemistry</i> , 2016, 55, 193-226.	10.4	3
310	Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle Growth. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e342.	5.1	62
311	Long noncoding RNAs in digestive system cancers: Functional roles, molecular mechanisms, and clinical implications (Review). <i>Oncology Reports</i> , 2016, 36, 1207-1218.	2.6	29
312	Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2305-2313.	0.7	17
313	Modified Nucleic Acids in Biology and Medicine. <i>RNA Technologies</i> , 2016, , .	0.3	3
314	Hairpin Ribozyme Genes Curtail Alcohol Drinking: from Rational Design to in vivo Effects in the Rat. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e335.	5.1	4
315	The contribution of adenines in the catalytic core of 10-23 DNAzyme improved by the 6-amino group modifications. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4462-4465.	2.2	11
316	Design Considerations for RNA Spherical Nucleic Acids (SNAs). <i>Bioconjugate Chemistry</i> , 2016, 27, 2124-2131.	3.6	39
317	Hepatic Stellate Cells in Liver Fibrosis and siRNA-Based Therapy. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2016, 172, 1-37.	1.6	31
318	Chaperonin-Dendrimer Conjugates for siRNA Delivery. <i>Advanced Science</i> , 2016, 3, 1600046.	11.2	28
319	The Emerging Roles of Long Noncoding RNA ROR (lincRNA-ROR) and its Possible Mechanisms in Human Cancers. <i>Cellular Physiology and Biochemistry</i> , 2016, 40, 219-229.	1.6	126

#	ARTICLE	IF	CITATIONS
321	Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity. <i>Scientific Reports</i> , 2016, 6, 36518.	3.3	24
322	A druggable target for rescuing microRNA defects. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4942-4946.	2.2	7
323	PolyAdenine cryogels for fast and effective RNA purification. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 146, 678-686.	5.0	24
324	Retroviral Analogues Differentially Affect Oligonucleotide Delivery and Toxin Trafficking. <i>ChemMedChem</i> , 2016, 11, 2506-2510.	3.2	3
325	An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the <i>CACNA1A</i> second cistron. <i>Science Translational Medicine</i> , 2016, 8, 347ra94.	12.4	51
326	Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems. <i>KONA Powder and Particle Journal</i> , 2016, 33, 63-85.	1.7	38
327	Biomedical Applications of DNA Nanomaterials Based on Metallic Nanoparticles and DNA Self-Assembled Nanostructures. <i>Chinese Journal of Chemistry</i> , 2016, 34, 283-290.	4.9	11
328	RNA therapeutics – The potential treatment for myocardial infarction. <i>Regenerative Therapy</i> , 2016, 4, 83-91.	3.0	5
329	ERK1 as a Therapeutic Target for Dendritic Cell Vaccination against High-Grade Gliomas. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1975-1987.	4.1	7
330	From the RNA world to the clinic. <i>Science</i> , 2016, 352, 1417-1420.	12.6	225
331	Editing the epigenome: technologies for programmable transcription and epigenetic modulation. <i>Nature Methods</i> , 2016, 13, 127-137.	19.0	341
332	Structural modifications in polymeric micelles to impart multifunctionality for improved drug delivery. <i>Therapeutic Delivery</i> , 2016, 7, 73-87.	2.2	9
333	Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2016, 64, 699-707.	3.7	38
334	Improving the osteogenesis of rat mesenchymal stem cells by chitosan-based-microRNA nanoparticles. <i>Carbohydrate Polymers</i> , 2016, 138, 49-58.	10.2	59
335	Rapid Exchange Between Free and Bound States in RNA-Dendrimer Polyplexes: Implications on the Mechanism of Delivery and Release. <i>Biomacromolecules</i> , 2016, 17, 154-164.	5.4	20
336	Sequence-non-specific effects generated by various types of RNA interference triggers. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2016, 1859, 306-314.	1.9	19
337	Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand. <i>Biomaterials</i> , 2016, 77, 98-110.	11.4	57
338	siRNA-Loaded Polyion Complex Micelle Decorated with Charge-Conversional Polymer Tuned to Undergo Stepwise Response to Intra-Tumoral and Intra-Endosomal pHs for Exerting Enhanced RNAi Efficacy. <i>Biomacromolecules</i> , 2016, 17, 246-255.	5.4	48

#	ARTICLE	IF	CITATIONS
339	RNAi nanomaterials targeting immune cells as an anti-tumor therapy: the missing link in cancer treatment?. <i>Materials Today</i> , 2016, 19, 29-43.	14.2	31
340	Fit for the Eye: Aptamers in Ocular Disorders. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 127-146.	3.6	103
341	Affinity approaches in RNAi-based therapeutics purification. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1021, 45-56.	2.3	12
342	Ultrasound-responsive microbubbles for sonography-guided siRNA delivery. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1139-1149.	3.3	39
343	Robust neuroprotective effects of intranasally delivered iNOS siRNA encapsulated in gelatin nanoparticles in the postischemic brain. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1219-1229.	3.3	40
344	Uptake Mechanism and Direct Translocation of a New CPP for siRNA Delivery. <i>Molecular Pharmaceutics</i> , 2016, 13, 1366-1374.	4.6	29
345	Vectorization of Nucleic Acids for Therapeutic Approach: Tutorial Review. <i>ACS Chemical Biology</i> , 2016, 11, 1180-1191.	3.4	23
346	RNA-Protein Complexes and Interactions. <i>Methods in Molecular Biology</i> , 2016, 1421, vii-viii.	0.9	0
347	In-depth study on the gene silencing capability of silica nanoparticles with different pore sizes: degree and duration of RNA interference. <i>RSC Advances</i> , 2016, 6, 27143-27150.	3.6	19
348	HIV-Induced Epigenetic Alterations in Host Cells. <i>Advances in Experimental Medicine and Biology</i> , 2016, 879, 27-38.	1.6	35
349	Progress and perspective of inorganic nanoparticle-based siRNA delivery systems. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 547-559.	5.0	75
350	Therapeutic Applications of Aptamer-Based Riboswitches. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 44-51.	3.6	24
351	Technological development of structural DNA/RNA-based RNAi systems and their applications. <i>Advanced Drug Delivery Reviews</i> , 2016, 104, 29-43.	13.7	30
352	The complement system in cancer: Ambivalence between tumour destruction and promotion. <i>Immunobiology</i> , 2017, 222, 45-54.	1.9	92
353	Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts. <i>Laryngoscope</i> , 2017, 127, E231-E237.	2.0	13
354	La Genética Clínica en la actualidad. <i>Medicina Clínica</i> , 2017, 149, 75-77.	0.6	4
355	The chemical evolution of oligonucleotide therapies of clinical utility. <i>Nature Biotechnology</i> , 2017, 35, 238-248.	17.5	816
356	Synthesis and properties of cross-linkable DNA duplex using 4-amino-2-oxo-6-vinyl-1,3,5-triazine. <i>Tetrahedron</i> , 2017, 73, 1424-1435.	1.9	3

#	ARTICLE	IF	CITATIONS
357	Aptamer-Conjugated Calcium Phosphate Nanoparticles for Reducing Diabetes Risk via Retinol Binding Protein 4 Inhibition. <i>Canadian Journal of Diabetes</i> , 2017, 41, 305-311.	0.8	10
358	Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy. <i>ACS Chemical Biology</i> , 2017, 12, 892-898.	3.4	175
359	Re-characterization of hammerhead ribozymes as molecular tools for intermolecular RNA cleavage. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 4681-4685.	2.8	3
361	Targeted protein knockdown using small molecule degraders. <i>Current Opinion in Chemical Biology</i> , 2017, 39, 46-53.	6.1	84
362	Research on genodermatoses using novel genome editing tools. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 783-789.	0.8	8
363	Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders. , 2017, , .		3
364	Novel benzopyran derivatives and their therapeutic applications: a patent review (2009-2016). <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 1031-1045.	5.0	22
365	Development of Excipient-Free Freeze-Dryable Unimolecular Hyperstar Polymers for Efficient siRNA Silencing. <i>ACS Macro Letters</i> , 2017, 6, 700-704.	4.8	23
366	Novel Chemically-modified DNzyme targeting Integrin alpha-4 RNA transcript as a potential molecule to reduce inflammation in multiple sclerosis. <i>Scientific Reports</i> , 2017, 7, 1613.	3.3	26
367	Microfluidic self-assembly of folate-targeted monomolecular siRNA-lipid nanoparticles. <i>Nanoscale</i> , 2017, 9, 7442-7453.	5.6	52
368	siRNA Therapeutics to Treat Liver Disorders. , 2017, , 159-190.		3
369	Oligonucleotide Therapy. , 2017, , 191-217.		0
370	Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 8, 132-143.	5.1	600
371	The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. <i>Pharmaceutical Research</i> , 2017, 34, 1339-1363.	3.5	158
372	Silencing of <i>BCR/ABL</i> Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates. <i>Nucleic Acid Therapeutics</i> , 2017, 27, 168-175.	3.6	9
373	Drug Target miRNA. <i>Methods in Molecular Biology</i> , 2017, , .	0.9	2
374	Rapid Generation of miRNA Inhibitor Leads by Bioinformatics and Efficient High-Throughput Screening Methods. <i>Methods in Molecular Biology</i> , 2017, 1517, 179-198.	0.9	14
375	Therapeutic Applications: Strategies and Molecules Targeting the IL-17/Th17 Pathway. , 2017, , 55-99.		0

#	ARTICLE	IF	CITATIONS
376	Evaluation of size-exclusion chromatography for the analysis of phosphorothioate oligonucleotides. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 136, 55-65.	2.8	18
377	<i>De novo</i> sequencing of highly modified therapeutic oligonucleotides by hydrophobic tag sequencing coupled with LC-MS. <i>Journal of Mass Spectrometry</i> , 2017, 52, 78-93.	1.6	2
378	The Presence of the Neuronal Nitric Oxide Synthase Isoform in the Intervertebral Disk. <i>Neurotoxicity Research</i> , 2017, 31, 148-161.	2.7	7
379	Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy. <i>Drug Delivery and Translational Research</i> , 2017, 7, 346-358.	5.8	26
380	Gold nanorod embedded large-pore mesoporous organosilica nanospheres for gene and photothermal cooperative therapy of triple negative breast cancer. <i>Nanoscale</i> , 2017, 9, 1466-1474.	5.6	39
382	Holistic and Affordable Analyses of MicroRNA Expression Profiles Using Tagged cDNA Libraries and a Multiplex Sequencing Strategy. <i>Methods in Molecular Biology</i> , 2017, 1654, 179-196.	0.9	4
383	Evaluation of antitumor activity of survivin short interfering RNA delivered by lipid nanoparticles in colon cancer in vitro and in vivo. <i>Oncology Letters</i> , 2017, 14, 2001-2008.	1.8	17
384	Dendrimers as Nanostructured Therapeutic Carriers. , 2017, , 139-166.		0
385	Biomedical applications of RNA-based devices. <i>Current Opinion in Biomedical Engineering</i> , 2017, 4, 106-115.	3.4	19
386	Regulating Bacterial Virulence with RNA. <i>Annual Review of Microbiology</i> , 2017, 71, 263-280.	7.3	67
387	Cationic nioplexes-in-polysaccharide-based hydrogels as versatile biodegradable hybrid materials to deliver nucleic acids. <i>Journal of Materials Chemistry B</i> , 2017, 5, 7756-7767.	5.8	12
388	Modulating the Cellular Immune Response of Oligonucleotides by Brush Polymer-Assisted Compaction. <i>Small</i> , 2017, 13, 1701432.	10.0	26
389	Forschung zu Genodermatosen durch neue Genom-Editing-Methoden. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 783-790.	0.8	1
390	Challenges and Perspectives in Nucleic Acid Enzyme Engineering. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2017, 170, 21-35.	1.1	5
392	Fate-Regulating Circuits in Viruses: From Discovery to New Therapy Targets. <i>Annual Review of Virology</i> , 2017, 4, 469-490.	6.7	20
394	Renal carcinoma/kidney progenitor cell chimera organoid as a novel tumourigenesis gene discovery model. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 1503-1515.	2.4	8
395	Targeting Herpes Simplex Virus-1 gD by a DNA Aptamer Can Be an Effective New Strategy to Curb Viral Infection. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 9, 365-378.	5.1	40
396	Strategies for Characterization of Enzymatic Nucleic Acids. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2017, 170, 37-58.	1.1	1

#	ARTICLE	IF	CITATIONS
397	Clinical Genetics today. <i>Medicina Clínica (English Edition)</i> , 2017, 149, 75-77.	0.2	2
399	Functional significance of exosomes applied in sepsis: A novel approach to therapy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 292-297.	3.8	36
400	A Vector-Based Short Hairpin RNA Targeting Aurora B Suppresses Human Prostatic Carcinoma Growth. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 112-119.	1.9	2
401	Gelatin nanoparticles: a potential candidate for medical applications. <i>Nanotechnology Reviews</i> , 2017, 6, 191-207.	5.8	117
402	Distinctive polymer micelle designed for siRNA delivery and reversal of <i>MDR1</i> gene-dependent multidrug resistance. , 2017, 105, 2093-2106.		10
403	Smart micelleplexes as a new therapeutic approach for RNA delivery. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 353-371.	5.0	24
404	Definition and identification of small RNA sponges: Focus on miRNA sequestration. <i>Methods</i> , 2017, 117, 35-47.	3.8	20
405	Induced protein degradation: an emerging drug discovery paradigm. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 101-114.	46.4	971
406	Influence of nucleotide modifications at the C2™ position on the Hoogsteen base-paired parallel-stranded duplex of poly(A) RNA. <i>Nucleic Acids Research</i> , 2017, 45, 10321-10331.	14.5	12
408	As Technologies for Nucleotide Therapeutics Mature, Products Emerge. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 9, 379-386.	5.1	24
409	The role of nanotechnology and chitosan-based biomaterials for tissue engineering and therapeutic delivery. , 2017, , 1-29.		10
410	<i>Legionella Pneumophila</i> and Dendrimers-Mediated Antisense Therapy. <i>Advanced Pharmaceutical Bulletin</i> , 2017, 7, 179-187.	1.4	7
411	Interleukin 3- receptor targeted exosomes inhibit <i>in vitro</i> and <i>in vivo</i> Chronic Myelogenous Leukemia cell growth. <i>Theranostics</i> , 2017, 7, 1333-1345.	10.0	266
412	Bioengineered nanomaterials for chemotherapy. , 2017, , 23-49.		8
413	Charomers™ Interleukin-6 Receptor Specific Aptamers for Cellular Internalization and Targeted Drug Delivery. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2641.	4.1	12
414	microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview. <i>Frontiers in Oncology</i> , 2017, 7, 255.	2.8	61
415	miR-146a regulates glucose induced upregulation of inflammatory cytokines extracellular matrix proteins in the retina and kidney in diabetes. <i>PLoS ONE</i> , 2017, 12, e0173918.	2.5	44
416	Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems. <i>KONA Powder and Particle Journal</i> , 2017, 34, 44-69.	1.7	19

#	ARTICLE	IF	CITATIONS
417	Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome. <i>Oncotarget</i> , 2017, 8, 9375-9387.	1.8	89
418	From huntingtin gene to \hat{A} Huntington \hat{A} 's disease-altering strategies. , 2017, , 251-276.		0
419	New insights into epigenetic modifications in heart failure. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 230-247.	3.0	8
420	Bionanomedicine: A \hat{A} panacea \hat{A} in Medicine?. <i>Makara Journal of Health Research</i> , 2017, 21, .	0.1	2
421	Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications. <i>Chemical Society Reviews</i> , 2018, 47, 3574-3620.	38.1	352
423	Assessment of External Guide Sequences \hat{A} ™ (EGS) Efficiency as Inducers of RNase P-Mediated Cleavage of mRNA Target Molecules. <i>Methods in Molecular Biology</i> , 2018, 1737, 89-98.	0.9	6
424	Cooperativity Principles in Self-Assembled Nanomedicine. <i>Chemical Reviews</i> , 2018, 118, 5359-5391.	47.7	129
425	Dynamic Behavior of RNA Nanoparticles Analyzed by AFM on a Mica/Air Interface. <i>Langmuir</i> , 2018, 34, 15099-15108.	3.5	35
426	Design and assessment of engineered CRISPR \hat{A} ™ Cpf1 and its use for genome editing. <i>Nature Protocols</i> , 2018, 13, 899-914.	12.0	40
427	Controlled release technology for anti-angiogenesis treatment of posterior eye diseases: Current status and challenges. <i>Advanced Drug Delivery Reviews</i> , 2018, 126, 145-161.	13.7	34
428	Synthesis and characterization of Ag \hat{A} -decorated poly(glycidyl methacrylate) microparticle design for the adsorption of nucleic acids. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1081-1082, 1-7.	2.3	16
429	Therapeutic applications of group I intron \hat{A} -based <i>trans</i> -splicing ribozymes. <i>Wiley Interdisciplinary Reviews RNA</i> , 2018, 9, e1466.	6.4	16
430	Non-coding RNAs, epigenetics, and cancer: tying it all together. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 55-73.	5.9	87
431	Nanotechnology-Based Strategies for siRNA Brain Delivery for Disease Therapy. <i>Trends in Biotechnology</i> , 2018, 36, 562-575.	9.3	139
432	Advances in lipid-lowering therapy through gene-silencing technologies. <i>Nature Reviews Cardiology</i> , 2018, 15, 261-272.	13.7	101
433	Nanoparticle delivery of RNA \hat{A} -based therapeutics to alter the vocal fold tissue response to injury. <i>Laryngoscope</i> , 2018, 128, E178-E183.	2.0	10
434	Molecular chemotherapeutic potential of butein: A concise review. <i>Food and Chemical Toxicology</i> , 2018, 112, 1-10.	3.6	36
435	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. <i>Chemical Reviews</i> , 2018, 118, 1599-1663.	47.7	64

#	ARTICLE	IF	CITATIONS
436	Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 16.	12.8	72
437	Journey of siRNA: Clinical Developments and Targeted Delivery. <i>Nucleic Acid Therapeutics</i> , 2018, 28, 209-224.	3.6	135
438	Hidden Structural Modules in a Cooperative RNA Folding Transition. <i>Cell Reports</i> , 2018, 22, 3240-3250.	6.4	20
439	Target-enrichment sequencing for detailed characterization of small RNAs. <i>Nature Protocols</i> , 2018, 13, 768-786.	12.0	9
440	Oligonucleotide therapeutics in neurodegenerative diseases. <i>RNA Biology</i> , 2018, 15, 1-8.	3.1	47
441	MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 224-233.	6.5	27
442	Topical delivery of TRP siRNA-loaded solid lipid nanoparticles confer reduced pain sensation via TRPV1 silencing, in rats. <i>Journal of Drug Targeting</i> , 2018, 26, 135-149.	4.4	14
443	Plant viral and bacteriophage delivery of nucleic acid therapeutics. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2018, 10, e1487.	6.1	25
444	Assessment and comparison of thermal stability of phosphorothioate-DNA, DNA, RNA, 2'-F RNA, and LNA in the context of Phi29 pRNA 3WJ. <i>Rna</i> , 2018, 24, 67-76.	3.5	41
445	Ki67 targeted strategies for cancer therapy. <i>Clinical and Translational Oncology</i> , 2018, 20, 570-575.	2.4	167
446	Co-Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects. <i>Advanced Healthcare Materials</i> , 2018, 7, 1700886.	7.6	96
447	Harnessing CRISPR/Cas systems for programmable transcriptional and post-transcriptional regulation. <i>Biotechnology Advances</i> , 2018, 36, 295-310.	11.7	87
449	Synthesis and Antisense Properties of 2'-F-Arabinouridine Modified Oligonucleotides with 4'-C-OMe Substituent. <i>Molecules</i> , 2018, 23, 2374.	3.8	5
450	Generating Two-Dimensional Repertoire of siRNA Linc-ROR and siRNA mRNA ARF6 from the lincRNA-RoR/miR-145/ARF6 expression Pathway that involved in the progression of Triple Negative Breast Cancer. <i>IOP Conference Series: Materials Science and Engineering</i> , 2018, 299, 012059.	0.6	0
451	Cholinium-Based Good's Buffers Ionic Liquids as Remarkable Stabilizers and Recyclable Preservation Media for Recombinant Small RNAs. <i>ACS Sustainable Chemistry and Engineering</i> , 2018, 6, 16645-16656.	6.7	24
452	Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus. <i>Frontiers in Immunology</i> , 2018, 9, 2478.	4.8	41
453	Aptamers: novelty tools for cancer biology. <i>Oncotarget</i> , 2018, 9, 26934-26953.	1.8	34
454	Self-Replicating RNA Viruses for RNA Therapeutics. <i>Molecules</i> , 2018, 23, 3310.	3.8	49

#	ARTICLE	IF	CITATIONS
455	A Robust Nanoparticle Platform for RNA Interference in Macrophages to Suppress Tumor Cell Migration. <i>Frontiers in Pharmacology</i> , 2018, 9, 1465.	3.5	13
456	Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 7727-7747.	6.7	181
457	Gene Therapy Approaches to Biological Pacemakers. <i>Journal of Cardiovascular Development and Disease</i> , 2018, 5, 50.	1.6	7
458	RNA Fibers as Optimized Nanoscaffolds for siRNA Coordination and Reduced Immunological Recognition. <i>Advanced Functional Materials</i> , 2018, 28, 1805959.	14.9	57
459	A RNA producing DNA hydrogel as a platform for a high performance RNA interference system. <i>Nature Communications</i> , 2018, 9, 4331.	12.8	47
460	Group I Intron-Based Therapeutics Through Trans-Splicing Reaction. <i>Progress in Molecular Biology and Translational Science</i> , 2018, 159, 79-100.	1.7	2
461	Elimination terminal fixed region screening and high-throughput kinetic determination of aptamer for lipocalin-1 by surface plasmon resonance imaging. <i>Analytica Chimica Acta</i> , 2018, 1043, 158-166.	5.4	8
463	Aptamer as Therapeutics for Cancer with Focus on Retinoblastoma. , 2018, , 147-194.		1
464	Templated synthesis of spherical RNA nanoparticles with gene silencing activity. <i>Chemical Communications</i> , 2018, 54, 11296-11299.	4.1	12
465	A General Overview on Non-coding RNA-Based Diagnostic and Therapeutic Approaches for Liver Diseases. <i>Frontiers in Pharmacology</i> , 2018, 9, 805.	3.5	20
466	Maximising success in multidrug formulation development: A review. <i>Journal of Controlled Release</i> , 2018, 283, 1-19.	9.9	28
467	Block Copolymer Micelles in Nanomedicine Applications. <i>Chemical Reviews</i> , 2018, 118, 6844-6892.	47.7	925
469	Biomolecular Therapeutics for HIV. , 2018, , 541-567.		2
470	Synthesis and properties of 4-aminomethyl-2-fluoro-modified RNA oligomers. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 4574-4582.	3.0	18
471	Chemical Protein Degradation Approach and its Application to Epigenetic Targets. <i>Chemical Record</i> , 2018, 18, 1681-1700.	5.8	33
472	A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey. <i>Molecules</i> , 2018, 23, 1302.	3.8	38
473	RNA Interference Therapies for an HIV-1 Functional Cure. <i>Viruses</i> , 2018, 10, 8.	3.3	36
474	Smart micelleplexes. , 2018, , 257-291.		6

#	ARTICLE	IF	CITATIONS
475	MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct. Nucleic Acid Therapeutics, 2018, 28, 285-296.	3.6	93
476	A basic insight into aptamer-drug conjugates (ApDCs). Biomaterials, 2018, 182, 216-226.	11.4	75
477	RNA-mediated therapies in myotonic dystrophy. Drug Discovery Today, 2018, 23, 2013-2022.	6.4	37
478	Methods and advances in RNA characterization and design. Methods, 2018, 143, 1-3.	3.8	1
479	Brain targeting with lipidic nanocarriers. , 2018, , 255-324.		2
480	Improved Cell Transfection of siRNA by pH-Responsive Nanomicelles Self-Assembled with mPEG- <i>b</i> -PHis- <i>b</i> -PEI Copolymers. ACS Applied Materials & Interfaces, 2018, 10, 21847-21860.	8.0	19
481	Chronic myelogenous leukemia on target. Cancer Medicine, 2018, 7, 3406-3410.	2.8	3
482	Synthetic bPNAs as allosteric triggers of hammerhead ribozyme catalysis. Methods in Enzymology, 2019, 623, 151-175.	1.0	6
484	Fluorescent Probe for Investigation of Influence of Ribonucleosides With Dâ€™Mannitol. , 2019, , .		0
485	Design of RNA-targeting macrocyclic peptides. Methods in Enzymology, 2019, 623, 339-372.	1.0	10
486	Bridged Nucleic Acids Reloaded. Molecules, 2019, 24, 2297.	3.8	21
487	Î±-Aminoisobutyric Acid-Containing Amphipathic Helical Peptide-Cyclic RGD Conjugation as a Potential Drug Delivery System for MicroRNA Replacement Therapy in Vitro. Molecular Pharmaceutics, 2019, 16, 4542-4550.	4.6	11
488	Single-cell kinetics of siRNA-mediated mRNA degradation. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 21, 102077.	3.3	6
489	Collagen-infilled 3D printed scaffolds loaded with miR-148b-transfected bone marrow stem cells improve calvarial bone regeneration in rats. Materials Science and Engineering C, 2019, 105, 110128.	7.3	45
490	The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer. Cells, 2019, 8, 1055.	4.1	145
491	Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics. Biochemical Pharmacology, 2019, 169, 113638.	4.4	40
492	Delivery of RIPK4 small interfering RNA for bladder cancer therapy using natural halloysite nanotubes. Science Advances, 2019, 5, eaaw6499.	10.3	43
493	Cationic Niosomes as Non-Viral Vehicles for Nucleic Acids: Challenges and Opportunities in Gene Delivery. Pharmaceutics, 2019, 11, 50.	4.5	59

#	ARTICLE	IF	CITATIONS
494	MoS ₂ -based biomaterials for cancer therapy. , 2019, , 141-161.		4
495	<p></p>Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach</p>International Journal of Nanomedicine, 2019, Volume 14, 3111-3128.	6.7	167
496	Long Noncoding RNAs in the Pathophysiology of Ischemic Stroke. NeuroMolecular Medicine, 2019, 21, 474-483.	3.4	39
497	Functionalization of SF/HAP Scaffold with GO-PEI-miRNA inhibitor Complexes to Enhance Bone Regeneration through Activating Transcription Factor 4. Theranostics, 2019, 9, 4525-4541.	10.0	43
498	Triplex Hybridization of siRNA with Bifacial Glycopolymer Nucleic Acid Enables Hepatocyte-Targeted Silencing. ACS Chemical Biology, 2019, 14, 1310-1318.	3.4	7
499	RNA targeting by an anthracycline drug: spectroscopic and <i>in silico</i> evaluation of epirubicin interaction with tRNA. Journal of Biomolecular Structure and Dynamics, 2020, 38, 1-11.	3.5	6
500	Smart-Responsive Nucleic Acid Nanoparticles (NANPs) with the Potential to Modulate Immune Behavior. Nanomaterials, 2019, 9, 611.	4.1	37
501	Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation. European Journal of Medicinal Chemistry, 2019, 174, 159-180.	5.5	37
502	Synergistic effects of 7-O-geranylquercetin and siRNAs on the treatment of human breast cancer. Life Sciences, 2019, 227, 145-152.	4.3	17
503	Systemic miRNA delivery by nontoxic nanoscale coordination polymers limits epithelial-to-mesenchymal transition and suppresses liver metastases of colorectal cancer. Biomaterials, 2019, 210, 94-104.	11.4	27
504	Development of simple isocratic HPLC methods for siRNA quantitation in lipid-based nanoparticles. Journal of Pharmaceutical and Biomedical Analysis, 2019, 172, 253-258.	2.8	4
505	Structural and Energetic Impact of Non-natural 7-Deaza-8-azaguanine, 7-Deaza-8-azaisoguanine, and Their 7-Substituted Derivatives on Hydrogen-Bond Pairing with Cytosine and Isocytosine. ChemBioChem, 2019, 20, 2262-2270.	2.6	4
506	Gene and Induced Pluripotent Stem Cell Therapy for Retinal Diseases. Annual Review of Genomics and Human Genetics, 2019, 20, 201-216.	6.2	32
507	Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention. Frontiers in Immunology, 2019, 10, 752.	4.8	49
508	ToGo-WF: prediction of RNA tertiary structures and RNA-RNA/protein interactions using the KNIME workflow. Journal of Computer-Aided Molecular Design, 2019, 33, 497-507.	2.9	5
509	Disulfide-Unit Conjugation Enables Ultrafast Cytosolic Internalization of Antisense DNA and siRNA. Angewandte Chemie, 2019, 131, 6683-6687.	2.0	15
510	Recent advances of stimuli-responsive systems based on transition metal dichalcogenides for smart cancer therapy. Journal of Materials Chemistry B, 2019, 7, 2588-2607.	5.8	29
511	Disulfide-Unit Conjugation Enables Ultrafast Cytosolic Internalization of Antisense DNA and siRNA. Angewandte Chemie - International Edition, 2019, 58, 6611-6615.	13.8	70

#	ARTICLE	IF	CITATIONS
512	From Oxygen to Sulfur and Back: Difluoro- <i>H</i> -phosphinothioates as a Turning Point in the Preparation of Difluorinated Phosphinates: Application to the Synthesis of Modified Dinucleotides. <i>Journal of Organic Chemistry</i> , 2019, 84, 5245-5260.	3.2	3
513	Self-Assembled Cationic β -Cyclodextrin Nanostructures for siRNA Delivery. <i>Molecular Pharmaceutics</i> , 2019, 16, 1358-1366.	4.6	47
514	RNA Dysregulation in Amyotrophic Lateral Sclerosis. <i>Frontiers in Genetics</i> , 2018, 9, 712.	2.3	134
515	Knockdown of Salivary IL-4 expression by siRNA induces apoptosis in colorectal cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 11531-11538.	2.6	5
516	Extracellular matrix-mediated regulation of cancer stem cells and chemoresistance. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 109, 90-104.	2.8	62
517	What is the future of cancer care? A technology foresight assessment of experts' expectations. <i>Economics of Innovation and New Technology</i> , 2019, 28, 635-652.	3.4	11
518	Licofelone-DPPC Interactions: Putting Membrane Lipids on the Radar of Drug Development. <i>Molecules</i> , 2019, 24, 516.	3.8	9
519	Current RNA-based Therapeutics in Clinical Trials. <i>Current Gene Therapy</i> , 2019, 19, 172-196.	2.0	82
520	Implementing Efficient Peptid-Mediated Delivery of RNA-Based Therapeutics to the Vocal Folds. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 640-644.	1.5	2
521	A U1i RNA that Enhances HIV-1 RNA Splicing with an Elongated Recognition Domain Is an Optimal Candidate for Combination HIV-1 Gene Therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 815-830.	5.1	9
522	The therapeutic and diagnostic potential of regulatory noncoding RNAs in medulloblastoma. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz023.	0.7	16
523	Nanomedicine for Imaging and Therapy of Pancreatic Adenocarcinoma. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 307.	4.1	27
524	Gene Silencing With siRNA (RNA Interference): A New Therapeutic Option During Ex Vivo Machine Liver Perfusion Preservation. <i>Liver Transplantation</i> , 2019, 25, 140-151.	2.4	47
525	Long Noncoding RNA GMAN, Up-regulated in Gastric Cancer Tissues, Is Associated With Metastasis in Patients and Promotes Translation of Ephrin A1 by Competitively Binding GMAN-AS. <i>Gastroenterology</i> , 2019, 156, 676-691.e11.	1.3	225
526	Screening of <i>BRCA1/2</i> deep intronic regions by targeted gene sequencing identifies the first germline <i>BRCA1</i> variant causing pseudoexon activation in a patient with breast/ovarian cancer. <i>Journal of Medical Genetics</i> , 2019, 56, 63-74.	3.2	26
527	Organ-on-a-chip models: Implications in drug discovery and clinical applications. <i>Journal of Cellular Physiology</i> , 2019, 234, 8352-8380.	4.1	162
528	Conformations of an RNA Helix-Junction-Helix Construct Revealed by SAXS Refinement of MD Simulations. <i>Biophysical Journal</i> , 2019, 116, 19-30.	0.5	16
529	Knockdown of salivary IL-4 expression by small interfering RNA induces apoptosis in breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 9392-9399.	2.6	9

#	ARTICLE	IF	CITATIONS
530	Bait-and-Switch Supramolecular Strategy To Generate Noncationic RNA-Polymer Complexes for RNA Delivery. <i>Biomacromolecules</i> , 2019, 20, 435-442.	5.4	31
531	Porous Silicon Nanoparticles for Applications in Nano-medicine. , 2019, , 211-226.		1
532	Silk Biomaterials-Mediated miRNA Functionalized Orthopedic Devices. <i>Tissue Engineering - Part A</i> , 2019, 25, 12-23.	3.1	20
533	siRNA therapeutics: a clinical reality. <i>Science China Life Sciences</i> , 2020, 63, 485-500.	4.9	191
534	Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1595.	6.1	19
535	Lipoplex-based therapeutics for effective oligonucleotide delivery: a compendious review. <i>Journal of Liposome Research</i> , 2020, 30, 313-335.	3.3	11
536	Fusion transcripts: Unexploited vulnerabilities in cancer?. <i>Wiley Interdisciplinary Reviews RNA</i> , 2020, 11, e1562.	6.4	21
537	Endocytosis Controls siRNA Efficiency: Implications for siRNA Delivery Vehicle Design and Cell-Specific Targeting. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 22-32.	3.6	16
538	Poly(lactide)-Based Reactive Micelles as a Robust Platform for mRNA Delivery. <i>Pharmaceutical Research</i> , 2020, 37, 30.	3.5	31
539	DARPin Ec1-LMWP protein scaffold in targeted delivery of siRNA molecules through EpCAM cancer stem cell marker. <i>Molecular Biology Reports</i> , 2020, 47, 7323-7331.	2.3	6
540	In silico studies of fluorinated chalcone and pyrazoline analogues as inhibitors for cervical cancer. <i>AIP Conference Proceedings</i> , 2020, , .	0.4	2
541	Development of Bioreduction Labile Protecting Groups for the 2'-Hydroxyl Group of RNA. <i>Organic Letters</i> , 2020, 22, 6006-6009.	4.6	3
542	PROTAC: A Novel Technology for Drug Development**. <i>ChemistrySelect</i> , 2020, 5, 13232-13247.	1.5	5
543	Advances of Nanoparticles for Leukemia Treatment. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 6478-6489.	5.2	19
544	Micro-RNA Analysis in Pulmonary Arterial Hypertension. <i>JACC Basic To Translational Science</i> , 2020, 5, 1149-1162.	4.1	24
546	Synthesis of Nucleobase-Modified RNA Oligonucleotides by Post-Synthetic Approach. <i>Molecules</i> , 2020, 25, 3344.	3.8	22
547	2'-fluoro-modified pyrimidines enhance affinity of RNA oligonucleotides to HIV-1 reverse transcriptase. <i>Rna</i> , 2020, 26, 1667-1679.	3.5	16
548	Optimal scanning concentration of MR imaging for tumor-bearing nude mice with SPIO-shRNA molecular probe. <i>Scientific Reports</i> , 2020, 10, 18655.	3.3	2

#	ARTICLE	IF	CITATIONS
549	Effect of Confinement in Nanopores on RNA Interactions with Functionalized Mesoporous Silica Nanoparticles. <i>Journal of Physical Chemistry B</i> , 2020, 124, 8549-8561.	2.6	10
550	Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation. <i>Seminars in Cancer Biology</i> , 2022, 80, 340-355.	9.6	51
551	RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges. <i>Pharmacological Reviews</i> , 2020, 72, 862-898.	16.0	192
552	Modified nucleic acids: replication, evolution, and next-generation therapeutics. <i>BMC Biology</i> , 2020, 18, 112.	3.8	77
553	Mathematical and computational models of RNA nanoclusters and their applications in data-driven environments. <i>Molecular Simulation</i> , 2020, 46, 1094-1115.	2.0	6
554	Compilation of antiviral treatments and strategies to fight fish viruses. <i>Reviews in Aquaculture</i> , 2021, 13, 1223-1254.	9.0	15
555	Design and Functional Validation of a Mutant Variant of the LncRNA <i>HOTAIR</i> to Counteract Snail Function in Epithelial-to-Mesenchymal Transition. <i>Cancer Research</i> , 2021, 81, 103-113.	0.9	38
556	Gene-based therapy in lipid management: the winding road from promise to practice. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 483-493.	4.1	20
557	Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody). <i>International Journal of Molecular Sciences</i> , 2020, 21, 3286.	4.1	4
558	Rationally designed Spot 42 RNAs with an inhibition/toxicity profile advantageous for engineering <i>E. coli</i> . <i>Engineering Reports</i> , 2020, 2, e12126.	1.7	0
559	Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 325.	3.7	40
560	Nano-Polyplexes Mediated Transfection of Runx2-shRNA Mitigates the Osteodifferentiation of Human Valvular Interstitial Cells. <i>Pharmaceutics</i> , 2020, 12, 507.	4.5	9
561	Targeting Oxidative Stress for Disease Prevention and Therapy: Where Do We Stand, and Where Do We Go from Here. <i>Molecules</i> , 2020, 25, 2653.	3.8	38
562	Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2020, 325, 235-248.	9.9	65
563	Intracellular Delivery of Antisense DNA and siRNA with Amino Groups Masked with Disulfide Units. <i>Chemical and Pharmaceutical Bulletin</i> , 2020, 68, 129-132.	1.3	5
564	The challenge and prospect of mRNA therapeutics landscape. <i>Biotechnology Advances</i> , 2020, 40, 107534.	11.7	221
565	Advances of aptamers screened by Cell-SELEX in selection procedure, cancer diagnostics and therapeutics. <i>Analytical Biochemistry</i> , 2020, 598, 113620.	2.4	50
566	Noncationic Material Design for Nucleic Acid Delivery. <i>Advanced Therapeutics</i> , 2020, 3, 1900206.	3.2	32

#	ARTICLE	IF	CITATIONS
567	Environmentâ€Recognizing DNAâ€Computation Circuits for the Intracellular Transport of Molecular Payloads for mRNA Imaging. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 6099-6107.	13.8	62
568	RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs. <i>Cells</i> , 2020, 9, 137.	4.1	246
569	Novel approaches for efficientÂ in vivo fermentation production of noncoding RNAs. <i>Applied Microbiology and Biotechnology</i> , 2020, 104, 1927-1937.	3.6	24
570	Environmentâ€Recognizing DNAâ€Computation Circuits for the Intracellular Transport of Molecular Payloads for mRNA Imaging. <i>Angewandte Chemie</i> , 2020, 132, 6155-6163.	2.0	11
571	Nanomedicine in osteosarcoma therapy: Micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 148, 88-106.	4.3	21
572	Short Interfering RNA (siRNA)-Based Therapeutics for Cartilage Diseases. <i>Regenerative Engineering and Translational Medicine</i> , 2020, 7, 283-290.	2.9	13
573	RNA-Targeted Therapies and High-Throughput Screening Methods. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2996.	4.1	24
574	The Role of Bone-Derived Exosomes in Regulating Skeletal Metabolism and Extraosseous Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 89.	3.7	32
575	Gene delivery into cells and tissues. , 2020, , 519-554.		3
576	Association of miR-760 with cancer: An overview. <i>Gene</i> , 2020, 747, 144648.	2.2	26
577	Hydrophobic Domain Structure of Linear-Dendritic Poly(ethylene glycol) Lipids Affects RNA Delivery of Lipid Nanoparticles. <i>Molecular Pharmaceutics</i> , 2020, 17, 1575-1585.	4.6	17
578	Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4908-4928.	6.4	38
579	Cyclodextrin based natural nanostructured carbohydrate polymers as effective non-viral siRNA delivery systems for cancer gene therapy. <i>Journal of Controlled Release</i> , 2021, 330, 1046-1070.	9.9	72
580	Effect of complexing lipids on cellular uptake and expression of messenger RNA in human skin explants. <i>Journal of Controlled Release</i> , 2021, 330, 1250-1261.	9.9	28
581	SIDT1-dependent absorption in the stomach mediates host uptake of dietary and orally administered microRNAs. <i>Cell Research</i> , 2021, 31, 247-258.	12.0	73
582	THERAPEUTIC OLIGONUCLEOTIDES, IMPURITIES, DEGRADANTS, AND THEIR CHARACTERIZATION BY MASS SPECTROMETRY. <i>Mass Spectrometry Reviews</i> , 2021, 40, 75-109.	5.4	35
583	Synthetic Technology of Noncoding RNAs Used in Bone Disease Research and Therapeutics. , 2021, , 141-157.		0
584	Dietary Modulation of the Gut Microbiomeâ€”Probing the Role of Small RNAs. , 2021, , 380-397.		0

#	ARTICLE	IF	CITATIONS
585	Layer by Layer Assembled Chitosan-Coated Gold Nanoparticles for Enhanced siRNA Delivery and Silencing. <i>International Journal of Molecular Sciences</i> , 2021, 22, 831.	4.1	35
586	Exosomes of mesenchymal stem cells as nano-cargos for anti-SARS-CoV-2 asRNAs. <i>Modern Medical Laboratory Journal</i> , 2021, 4, 11-18.	0.4	5
587	The journey of noncoding RNA from bench to clinic. , 2021, , 165-201.		2
588	Recent Advances in Nanocarriers Used for Selective Gene Silencing Therapy. <i>Nanomedicine and Nanotoxicology</i> , 2021, , 183-221.	0.2	0
589	Mesoporous silica nanoparticles combined with AKR1C3 siRNA inhibited the growth of castration-resistant prostate cancer by suppressing androgen synthesis in vitro and in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2021, 540, 83-89.	2.1	9
590	Oligonucleotide-Based Approaches to Inhibit Dengue Virus Replication. <i>Molecules</i> , 2021, 26, 956.	3.8	7
591	Nanosized Particles Assembled by a Recombinant Virus Protein Are Able to Encapsulate Negatively Charged Molecules and Structured RNA. <i>Polymers</i> , 2021, 13, 858.	4.5	1
592	Site-Selective Artificial Ribonucleases: Renaissance of Oligonucleotide Conjugates for Irreversible Cleavage of RNA Sequences. <i>Molecules</i> , 2021, 26, 1732.	3.8	6
593	Efficacy, accumulation, and transcriptional profile of anti-HIV shRNAs expressed from human U6, 7SK, and H1 promoters. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 23, 1020-1034.	5.1	10
594	Emerging role of RNA interference in immune cells engineering and its therapeutic synergism in immunotherapy. <i>British Journal of Pharmacology</i> , 2021, 178, 1741-1755.	5.4	12
595	siRNA Therapeutics: Future Promise for Neurodegenerative Diseases. <i>Current Neuropharmacology</i> , 2021, 19, 1896-1911.	2.9	10
596	Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology. <i>Current Medicinal Chemistry</i> , 2021, 28, 1304-1327.	2.4	8
597	Emerging Roles of Long Non-coding RNAs in Uterine Leiomyoma Pathogenesis: a Review. <i>Reproductive Sciences</i> , 2022, 29, 1086-1101.	2.5	9
598	Silencing Antibiotic Resistance with Antisense Oligonucleotides. <i>Biomedicines</i> , 2021, 9, 416.	3.2	13
599	DoçD°Ñ•ÑD;DµD°Ñ,ÑED¾4D¼DµÑ,ÑED,Ñ±D½D,D¹ D°D½D°D»Ñ-D· D¾4D»Ñ-D¾¾ÑED,D±D¾4D½ÑfD°D»DµD¾4Ñ,D,DÑ-D² ÑÑfD¹		
601	TREX1 as a Novel Immunotherapeutic Target. <i>Frontiers in Immunology</i> , 2021, 12, 660184.	4.8	36
602	The Peptide Functionalized Inorganic Nanoparticles for Cancer-Related Bioanalytical and Biomedical Applications. <i>Molecules</i> , 2021, 26, 3228.	3.8	17
603	RNA Sequencing in Potentially Malignant Disorders. , 0, , .		0

#	ARTICLE	IF	CITATIONS
605	Long noncoding RNA AFAP1-AS1 promotes tumor progression and invasion by regulating the miR-2110/Sp1 axis in triple-negative breast cancer. <i>Cell Death and Disease</i> , 2021, 12, 627.	6.3	22
606	CLEC3B Identified as a Potential Lung Cancer Biomarker in Serum by Aptamer-Capture Technology. <i>ChemistrySelect</i> , 2021, 6, 5640-5645.	1.5	9
607	Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device. <i>Nano Letters</i> , 2021, 21, 5671-5680.	9.1	120
608	Competing Endogenous RNAs in Cervical Carcinogenesis: A New Layer of Complexity. <i>Processes</i> , 2021, 9, 991.	2.8	1
609	Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2525-2538.	2.4	17
610	Noncoding RNA therapeutics – challenges and potential solutions. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 629-651.	46.4	749
611	Hydrophobic Tagging-Mediated Degradation of Transcription Coactivator SRC-1. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6407.	4.1	16
612	An overview of rational design of mRNA-based therapeutics and vaccines. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1307-1317.	5.0	37
613	Synthesis of KUE-siRNA Conjugates for Prostate Cancer Cell-Targeted Gene Silencing. <i>ChemBioChem</i> , 2021, 22, 2888-2895.	2.6	4
614	From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. <i>Molecular Aspects of Medicine</i> , 2021, 81, 101003.	6.4	13
615	A deep learning model for predicting next-generation sequencing depth from DNA sequence. <i>Nature Communications</i> , 2021, 12, 4387.	12.8	26
616	Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. , 2022, 230, 107967.		40
617	NMR chemical shift assignments of RNA oligonucleotides to expand the RNA chemical shift database. <i>Biomolecular NMR Assignments</i> , 2021, 15, 479-490.	0.8	5
618	Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120835.	5.2	48
619	siRNA: Mechanism of action, challenges, and therapeutic approaches. <i>European Journal of Pharmacology</i> , 2021, 905, 174178.	3.5	143
620	Cryo-EM and antisense targeting of the 28-kDa frameshift stimulation element from the SARS-CoV-2 RNA genome. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 747-754.	8.2	91
623	The infinite possibilities of RNA therapeutics. <i>Journal of Industrial Microbiology and Biotechnology</i> , 2021, 48, .	3.0	15
624	Supramolecular self-assembled DNA nanosystem for synergistic chemical and gene regulations on cancer cells. <i>Angewandte Chemie</i> , 0, , .	2.0	0

#	ARTICLE	IF	CITATIONS
625	Supramolecular Self-Assembled DNA Nanosystem for Synergistic Chemical and Gene Regulations on Cancer Cells. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 25557-25566.	13.8	36
626	New RNA-Based Breakthroughs in Alzheimer's Disease Diagnosis and Therapeutics. <i>Pharmaceutics</i> , 2021, 13, 1397.	4.5	8
627	The development and improvement of ribonucleic acid therapy strategies. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 997-1013.	5.1	11
628	Site-directed RNA editing: recent advances and open challenges. <i>RNA Biology</i> , 2021, 18, 41-50.	3.1	31
629	New approaches in extracellular vesicle engineering for improving the efficacy of anti-cancer therapies. <i>Seminars in Cancer Biology</i> , 2021, 74, 62-78.	9.6	27
630	Electrochemical aptasensor for NS1 detection: Towards a fast dengue biosensor. <i>Talanta</i> , 2021, 233, 122527.	5.5	27
631	A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity. <i>Theranostics</i> , 2021, 11, 6833-6846.	10.0	65
632	Synthesis, Structural, and Conformational Analysis of 4-alkyl-2'-ethyluridine Modified Nucleosides. <i>European Journal of Organic Chemistry</i> , 2021, 2021, 924-932.	2.4	6
633	Functional roles of antisense enhancer RNA for promoting prostate cancer progression. <i>Theranostics</i> , 2021, 11, 1780-1794.	10.0	24
634	Multifunctional Nanodelivery Platform for Maximizing Nucleic Acids Combination Therapy. <i>Methods in Molecular Biology</i> , 2020, 2115, 79-90.	0.9	4
635	Invention and Early History of Gappers. <i>Methods in Molecular Biology</i> , 2020, 2176, 3-19.	0.9	13
636	Gene Therapy Vectors. <i>SpringerBriefs in Biochemistry and Molecular Biology</i> , 2014, , 27-33.	0.3	1
637	Sequence-Defined Oligoaminoamides for the Delivery of siRNAs. <i>Methods in Molecular Biology</i> , 2015, 1206, 15-27.	0.9	11
638	Targeting bcr-abl Transcripts with siRNAs in an Imatinib-Resistant Chronic Myeloid Leukemia Patient: Challenges and Future Directions. <i>Methods in Molecular Biology</i> , 2015, 1218, 277-292.	0.9	8
639	RNAi-Mediated Resistance to Viruses in Genetically Engineered Plants. <i>Methods in Molecular Biology</i> , 2015, 1287, 81-92.	0.9	14
640	Small Non-Coding RNAs and Aptamers in Diagnostics and Therapeutics. <i>Methods in Molecular Biology</i> , 2015, 1296, 225-233.	0.9	2
641	Methods for Assembling B-Cell Lymphoma Specific and Internalizing Aptamer-siRNA Nanoparticles Via the Sticky Bridge. <i>Methods in Molecular Biology</i> , 2015, 1297, 169-185.	0.9	8
642	Loading of Argonaute Protein with Small Duplex RNA in Cellular Extracts. <i>Methods in Molecular Biology</i> , 2016, 1421, 53-67.	0.9	1

#	ARTICLE	IF	CITATIONS
643	Screening Inhibitory Potential of Anti-HIV RT RNA Aptamers. <i>Methods in Molecular Biology</i> , 2014, 1103, 11-29.	0.9	9
644	Design and Evaluation of Clinically Relevant SOFA-HDV Ribozymes Targeting HIV RNA. <i>Methods in Molecular Biology</i> , 2014, 1103, 31-43.	0.9	14
645	Targeting Heat Shock Proteins in Colorectal Cancer. <i>Heat Shock Proteins</i> , 2015, , 345-379.	0.2	2
646	Modified Antisense Oligonucleotides and Their Analogs in Therapy of Neuromuscular Diseases. <i>RNA Technologies</i> , 2016, , 243-271.	0.3	4
647	RNA Nanotechnology Approach for Targeted Delivery of RNA Therapeutics Using Cell-Internalizing Aptamers. , 2013, , 395-423.		1
648	Control of Gene Expression by RNAi: A Revolution in Functional Genomics. , 2017, , 17-57.		2
649	Small Interfering RNAs and RNA Therapeutics in Cardiovascular Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1229, 369-381.	1.6	6
650	Dichotomy of complement system: Tumorigenesis or destruction. <i>Immunology Letters</i> , 2020, 223, 89-96.	2.5	4
651	Therapeutic Potential of Ribozymes. <i>RSC Drug Discovery Series</i> , 2019, , 434-452.	0.3	4
652	Therapeutic potential of miR-21 regulation by human peripheral blood derived-small extracellular vesicles in myocardial infarction. <i>Clinical Science</i> , 2020, 134, 985-999.	4.3	8
656	Gene therapy and genome surgery in the retina. <i>Journal of Clinical Investigation</i> , 2018, 128, 2177-2188.	8.2	111
657	Clinical applications of microRNAs. <i>F1000Research</i> , 2013, 2, 136.	1.6	126
659	Lipidoid Nanoparticles for siRNA Delivery to the Intestinal Epithelium: In Vitro Investigations in a Caco-2 Model. <i>PLoS ONE</i> , 2015, 10, e0133154.	2.5	36
660	Molecular simulations and Markov state modeling reveal the structural diversity and dynamics of a theophylline-binding RNA aptamer in its unbound state. <i>PLoS ONE</i> , 2017, 12, e0176229.	2.5	29
661	RNA therapeutics: RNAi and antisense mechanisms and clinical applications. <i>Postdoc Journal</i> , 2016, 4, 35-50.	0.4	148
662	Short-interference RNAs: becoming medicines. <i>EXCLI Journal</i> , 2015, 14, 714-46.	0.7	15
663	Sense-antisense gene-pairs in breast cancer and associated pathological pathways. <i>Oncotarget</i> , 2015, 6, 42197-42221.	1.8	20
664	Everything You Always Wanted to Know About CADY-Mediated siRNA Delivery* (* But Afraid to Ask). <i>Current Pharmaceutical Design</i> , 2013, 19, 2869-2877.	1.9	22

#	ARTICLE	IF	CITATIONS
665	MicroRNA: Promising Roles in Cancer Therapy. <i>Current Pharmaceutical Biotechnology</i> , 2020, 21, 1186-1203.	1.6	18
666	Targeting ENaC as a Molecular Suspect in Cystic Fibrosis. <i>Current Drug Targets</i> , 2015, 16, 951-957.	2.1	6
667	Nano-enhanced Optical Gene Delivery to Retinal Degenerated Mice. <i>Current Gene Therapy</i> , 2019, 19, 318-329.	2.0	9
668	Oligonucleotide Aptamers for Glioma Targeting: An Update. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2015, 15, 126-137.	1.1	13
669	RNA Interference for the Treatment of Papillomavirus Disease. <i>The Open Virology Journal</i> , 2012, 6, 204-215.	1.8	12
670	TiO ₂ and Deoxyribozyme Nanocomposites as Delivery System and Efficient Site-Specific Agents for Cleavage of RNA Targets. <i>Drug Delivery Letters</i> , 2014, 4, 142-147.	0.5	7
671	Mediator kinase module and human tumorigenesis. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2015, 50, 393-426.	5.2	88
672	Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs. <i>Acta Naturae</i> , 2013, 5, 35-53.	1.7	21
673	Smart systems related to polypeptide sequences. <i>AIMS Materials Science</i> , 2016, 3, 289-323.	1.4	6
674	Therapeutic Potential of Anti-HIV RNA-loaded Exosomes. <i>Biomedical and Environmental Sciences</i> , 2018, 31, 215-226.	0.2	8
675	Decoding epigenetic codes: new frontiers in exploring recovery from spinal cord injury. <i>Neural Regeneration Research</i> , 2020, 15, 1613.	3.0	13
676	RNA interference and its role in cancer therapy. <i>Advanced Pharmaceutical Bulletin</i> , 2014, 4, 313-21.	1.4	146
677	Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression. <i>Cellular and Molecular Neurobiology</i> , 2021, , 1.	3.3	2
678	Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy. <i>Scientific Reports</i> , 2021, 11, 20083.	3.3	3
679	Nanomedicines for Systemic Delivery of RNAi Therapeutics. <i>Advances in Delivery Science and Technology</i> , 2013, , 127-142.	0.4	0
680	Potentials of RNA Aptamers for Viral Detection and Treatment. , 2013, , 467-482.		0
681	MicroRNAs: Biology and Role in RNA Nanotechnology. , 2013, , 551-562.		0
682	Nano-encapsulation of Oligonucleotides for Therapeutic Use. <i>Nucleic Acids and Molecular Biology</i> , 2014, , 245-260.	0.2	0

#	ARTICLE	IF	CITATIONS
683	Aptamers as Molecular Smugglers. , 2014, , 271-292.		0
684	Development therapeutic system by exosomal DDS of nucleic acid drugs. Drug Delivery System, 2014, 29, 134-139.	0.0	0
685	Challenges and Opportunities for Oligonucleotide-Based Therapeutics by Antisense and RNA Interference Mechanisms. , 2014, , 227-242.		0
686	Targeting Noncoding RNA for Treatment of Autism Spectrum Disorders. , 2014, , 203-228.		0
687	MicroRNAs with Impact on Adipose Tissue Inflammation in Obesity. , 2015, , 163-184.		0
688	Gene Therapy for the Treatment of Cancer: From Laboratory to Bedside. , 2015, , 1045-1064.		0
689	RNA and DNA nanoparticles for triggering RNA interference. RNA & Disease (Houston, Tex), 0, , .	1.0	0
691	RNA modified with acyclic threoninol nucleic acids for RNA interference. RNA & Disease (Houston, Tex) Tj ETQq1 1 0.784314 ggBT /Over	1.0	0
692	Multifunctional Bile Acid Derivatives as Efficient RNA Transporters (Carriers). Journal of Pharmaceutics & Drug Delivery Research, 2016, 5, .	0.0	2
695	Non-Coding Ribonucleic Acid: A New Anticancer Drug Target. Journal of Pharmacovigilance, 2016, 4, .	0.2	0
696	The anti-melanoma activity and oncogenic targets of hsa-miR-15a-5p. RNA & Disease (Houston, Tex), 0, , .	1.0	10
697	Rolling Circle Transcription for the Self-Assembly of Multimeric RNAi Structures and Its Applications in Nanomedicine. Methods in Molecular Biology, 2017, 1632, 65-74.	0.9	0
699	Implementation of Nanoparticles in Cancer Therapy. , 2017, , 1212-1257.		0
700	Bioinformatics Designing of 10-23 Deoxyribozyme against Coding Region of Beta-galactosidase Gene. Research in Molecular Medicine, 2017, 5, 28-33.	0.2	0
701	Study of the interaction between mannitol and nucleosides using fluorescent probe. Reports National Academy of Science of Ukraine, 2017, , 85-90.	0.1	2
702	Molecular docking study of oligonucleotides with D-mannitol. Visnik Ukrains Kogo Tovaristva Genetikiv I Selekcioneriv, 2017, 15, 64-68.	0.2	0
703	RNA Interference Therapeutics and Human Diseases. , 2018, , 477-490.		0
706	RNA Interference Therapeutics and Human Diseases. Advances in Medical Diagnosis, Treatment, and Care, 2019, , 69-83.	0.1	0

#	ARTICLE	IF	CITATIONS
707	Delivery of therapeutic miRNAs using nanoscale zeolitic imidazolate framework for accelerating vascularized bone regeneration. <i>Chemical Engineering Journal</i> , 2022, 430, 132867.	12.7	23
708	Hitching a Ride: Enhancing Nucleic Acid Delivery into Target Cells Through Nanoparticles. <i>Environmental Chemistry for A Sustainable World</i> , 2020, , 373-457.	0.5	2
710	Novel suction-based in vivo cutaneous DNA transfection platform. <i>Science Advances</i> , 2021, 7, eabj0611.	10.3	17
711	RNA Nanotechnology Approach for Targeted Delivery of RNA Therapeutics Using Cell-Internalizing Aptamers. , 2013, , 395-423.		1
712	Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs. <i>Acta Naturae</i> , 2013, 5, 35-53.	1.7	9
713	Aptamers: problems, solutions and prospects. <i>Acta Naturae</i> , 2013, 5, 34-43.	1.7	116
714	Network Theory Tools for RNA Modeling. <i>WSEAS Transactions on Mathematics</i> , 2013, 9, 941-955.	0.5	20
715	RNA interference targeting enhancer of polycomb1 exerts anti-tumor effects in lung cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 361-7.	0.5	2
717	The anti-melanoma activity and oncogenic targets of hsa-miR-15a-5p. <i>RNA & Disease (Houston, Tex)</i> , 2016, 3, .	1.0	9
718	How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2019, 30, 114-127.	0.7	143
719	Emerging roles of lncRNA in cancer and therapeutic opportunities. <i>American Journal of Cancer Research</i> , 2019, 9, 1354-1366.	1.4	162
720	RNA and DNA nanoparticles for triggering RNA interference. <i>RNA & Disease (Houston, Tex)</i> , 2015, 2, .	1.0	0
721	sEVsRVG ^Δ selectively delivers antiviral siRNA to fetus brain, inhibits ZIKV infection and mitigates ZIKV-induced microcephaly in mouse model. <i>Molecular Therapy</i> , 2022, 30, 2078-2091.	8.2	22
722	Innate and adaptive resistance to RNAi: a major challenge and hurdle to the development of double stranded RNA-based pesticides. <i>3 Biotech</i> , 2021, 11, 498.	2.2	2
723	Relating Mobility of dsRNA in Nanoporous Silica Particles to Loading and Release Behavior. <i>ACS Applied Bio Materials</i> , 2021, 4, 8267-8276.	4.6	0
724	The Treatment Progress of Collagen VI Related Congenital Muscular Dystrophy. <i>Advances in Clinical Medicine</i> , 2021, 11, 6013-6017.	0.0	0
725	Non-viral vectors for RNA delivery. <i>Journal of Controlled Release</i> , 2022, 342, 241-279.	9.9	100
726	Aptamer-Enabled Nanomaterials for Therapeutics, Drug Targeting and Imaging. <i>Cells</i> , 2022, 11, 159.	4.1	30

#	ARTICLE	IF	CITATIONS
727	Recent advances of chitosan-based nanoparticles for biomedical and biotechnological applications. <i>International Journal of Biological Macromolecules</i> , 2022, 203, 379-388.	7.5	71
728	Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 343, 564-583.	9.9	21
729	COVID-19â€™The disease. , 2022, , 35-69.		0
730	Visualizing RNA Structures by SAXS-Driven MD Simulations. <i>Frontiers in Bioinformatics</i> , 2022, 2, .	2.1	12
731	Ultraviolet Photodissociation and Activated Electron Photodetachment Mass Spectrometry for Top-Down Sequencing of Modified Oligoribonucleotides. <i>Journal of the American Society for Mass Spectrometry</i> , 2022, 33, 510-520.	2.8	9
732	Dually Active Polycation/miRNA Nanoparticles for the Treatment of Fibrosis in Alcohol-Associated Liver Disease. <i>Pharmaceutics</i> , 2022, 14, 669.	4.5	6
733	Aptamer-drug conjugates: New probes for imaging and targeted therapy. <i>Biosensors and Bioelectronics: X</i> , 2022, 10, 100126.	1.7	3
734	Multimeric RNAs for efficient RNA-based therapeutics and vaccines. <i>Journal of Controlled Release</i> , 2022, 345, 770-785.	9.9	3
735	Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules. <i>Biomedicines</i> , 2021, 9, 1823.	3.2	7
736	<i>Trans</i>â€™cleaving hammerhead ribozyme in specific regions can improve knockdown efficiency in vivo. <i>Journal of Cellular Biochemistry</i> , 2022, , .	2.6	2
737	Binding properties of [Ru(phen)2(11-R-dppz)]2+ (R=â€ or CN) with poly(A)â€™poly(U) duplex RNA. <i>Journal of Inorganic Biochemistry</i> , 2022, 232, 111833.	3.5	3
738	Elimination of Off-Target Effect by Chemical Modification of 5â€™-End of siRNA. <i>Nucleic Acid Therapeutics</i> , 2022, 32, 438-447.	3.6	7
739	Recent development of aptamer conjugated chitosan nanoparticles as cancer therapeutics. <i>International Journal of Pharmaceutics</i> , 2022, 620, 121751.	5.2	38
740	Dual Inhibitions on Glucose/Glutamine Metabolisms for Nontoxic Pancreatic Cancer Therapy. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 21836-21847.	8.0	14
741	RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	5
742	Facile fabrication of nanofibrous ion-exchange chromatography membrane with aminated surface for highly efficient RNA separation and purification. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2022, 648, 129160.	4.7	2
743	Serum albumin and nucleic acids biodistribution: From molecular aspects to biotechnological applications. <i>IUBMB Life</i> , 2022, 74, 866-879.	3.4	4
744	Application of vinyl polymerâ€™based materials as nucleic acids carriers in cancer therapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 0, , .	6.1	0

#	ARTICLE	IF	CITATIONS
745	The promising novel therapies for familial hypercholesterolemia. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, .	2.1	12
746	Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	9.1	52
747	Second Generation Synthesis of Modified Dinucleotide Analogues Featuring a Difluorophosphin(othio)yl Linkage. <i>European Journal of Organic Chemistry</i> , 2022, 2022, .	2.4	1
748	Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9507-9530.	6.4	14
749	Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. <i>Journal of Clinical Medicine</i> , 2022, 11, 3884.	2.4	22
750	<sc>CD33</sc>-targeting extracellular vesicles deliver antisense oligonucleotides against <sc>FLT3</sc> and <sc>miR</sc>-125b for specific treatment of acute myeloid leukaemia. <i>Cell Proliferation</i> , 2022, 55, .	5.3	7
751	Applications of self-replicating RNA. <i>International Review of Cell and Molecular Biology</i> , 2022, , .	3.2	3
753	Coaxial Synthesis of PEI-Based Nanocarriers of Encapsulated RNA-Therapeutics to Specifically Target Muscle Cells. <i>Biomolecules</i> , 2022, 12, 1012.	4.0	4
754	Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules. <i>Current Medicinal Chemistry</i> , 2023, 30, 1576-1622.	2.4	1
755	Development and application of ribonucleic acid therapy strategies against COVID-19. <i>International Journal of Biological Sciences</i> , 2022, 18, 5070-5085.	6.4	18
756	Biosensors based on functional nucleic acids and isothermal amplification techniques. <i>Talanta</i> , 2023, 253, 123977.	5.5	24
757	Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy. <i>Molecules</i> , 2022, 27, 5607.	3.8	12
758	miR-146a-5p-modified hUCMSC-derived exosomes facilitate spinal cord function recovery by targeting neurotoxic astrocytes. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	5.5	22
759	A perspective on oligonucleotide therapy: Approaches to patient customization. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	23
760	Nucleic Acid Delivery to the Vascular Endothelium. <i>Molecular Pharmaceutics</i> , 2022, 19, 4466-4486.	4.6	2
761	Preparation, characterization, and in-vitro cytotoxicity of nanoliposomes loaded with anti-tubercular drugs and TGF- β 1 siRNA for improving spinal tuberculosis therapy. <i>BMC Infectious Diseases</i> , 2022, 22, .	2.9	6
762	Extracellular Vesicles and Their Roles in the Tumor Immune Microenvironment. <i>Journal of Clinical Medicine</i> , 2022, 11, 6892.	2.4	8
763	Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy. <i>Pharmaceutics</i> , 2022, 15, 1573.	3.8	11

#	ARTICLE	IF	CITATIONS
764	Tellurium-Modified Nucleosides, Nucleotides, and Nucleic Acids with Potential Applications. <i>Molecules</i> , 2022, 27, 8379.	3.8	1
765	In Silico Study of the Binding of Daunomycin and Phenylalanine Transfer RNA: Probe Molecular Recognition for Structure-Based Drug Design. <i>Molecular Systems Design and Engineering</i> , 0, , .	3.4	1
766	Streptavidin-Saporin: Converting Biotinylated Materials into Targeted Toxins. <i>Toxins</i> , 2023, 15, 181.	3.4	2
767	Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery. <i>Nanoscale Advances</i> , 2023, 5, 1853-1869.	4.6	8
768	Recent advances in using liposomes for delivery of nucleic acid-based therapeutics. <i>OpenNano</i> , 2023, 11, 100132.	4.8	16
769	Aid or Antagonize: Nuclear Long Noncoding RNAs Regulate Host Responses and Outcomes of Viral Infections. <i>Cells</i> , 2023, 12, 987.	4.1	3
770	Development of Cationic Lipid LAH4-L1 siRNA Complexes for Focused Ultrasound Enhanced Tumor Uptake. <i>Molecular Pharmaceutics</i> , 0, , .	4.6	1
771	Nanotechnology-enabled gene delivery for cancer and other genetic diseases. <i>Expert Opinion on Drug Delivery</i> , 2023, 20, 523-540.	5.0	2
772	RNase P Ribozyme Effectively Inhibits Human CC-Chemokine Receptor 5 Expression and Human Immunodeficiency Virus 1 Infection. , 2023, 3, 93-103.		0
773	RNA-based Therapeutics: Master Regulator for Bioengineering Systems in Medicine World. <i>Current Biotechnology</i> , 2023, 12, , .	0.4	0
774	Mapping of RNase P Ribozyme Regions in Proximity with a Human RNase P Subunit Protein Using Fe(II)-EDTA Cleavage and Nuclease Footprint Analyses. <i>Methods in Molecular Biology</i> , 2023, , 55-67.	0.9	0
775	miRNAs in Bone Repair. , 2015, , 507-537.		0
776	Outils du ciblage thÃ©rapeutique. , 2023, , 167-179.		0
777	Regenerative Potential of Injured Spinal Cord in the Light of Epigenetic Regulation and Modulation. <i>Cells</i> , 2023, 12, 1694.	4.1	3
778	The application of extracellular vesicles in colorectal cancer metastasis and drug resistance: recent advances and trends. <i>Journal of Nanobiotechnology</i> , 2023, 21, , .	9.1	1
779	Different cellular barriers to RNA therapeutics and strategies to overcome. <i>International Journal of Surgery</i> , 2024, 110, 571-573.	2.7	0
780	Separation and characterization of biomacromolecules, bionanoparticles, and biomicroparticles using flow field-flow fractionation: Current applications and prospects. <i>TrAC - Trends in Analytical Chemistry</i> , 2023, 164, 117114.	11.4	5
781	Process and Bioprocess Analysis. <i>Lecture Notes in Quantum Chemistry II</i> , 2023, , 309-334.	0.3	0

#	ARTICLE	IF	CITATIONS
782	Building with DNA: From Curiosity-Driven Research to Practice. <i>Natural Computing Series</i> , 2023, , 173-188.	2.2	0
783	Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST. <i>IScience</i> , 2023, 26, 107284.	4.1	0
784	Enhanced anticancer activity of siRNA and drug codelivered by anionic biopolymer: overcoming electrostatic repulsion. <i>Nanomedicine</i> , 2023, 18, 855-874.	3.3	0
785	pH-Responsive Dynaplexes as Potent Apoptosis Inductors by Intracellular Delivery of Survivin siRNA. <i>Biomacromolecules</i> , 2023, 24, 3742-3754.	5.4	1
786	Aptamers as Theranostics in Cardiovascular Diseases. <i>Journal of Nanotheranostics</i> , 2023, 4, 408-428.	3.1	0
787	Stability and mechanism of threose nucleic acid toward acid-mediated degradation. <i>Nucleic Acids Research</i> , 2023, 51, 9542-9551.	14.5	4
788	Targeted protein degradation: A promising approach for cancer treatment. <i>Journal of Pharmaceutical Analysis</i> , 2023, , .	5.3	0
789	An insight of different classes of RNA-based therapeutic, nanodelivery and clinical status: current landscape. <i>Current Research in Biotechnology</i> , 2023, , 100150.	3.7	0
790	Liver factor B silencing to cure C3 glomerulopathy: Evidence from a mouse model of complement dysregulation. <i>Molecular Immunology</i> , 2023, 161, 25-32.	2.2	1
791	Stem Cells, Derived Exosomes, and Associated Signaling Molecules in Neuroprotection. , 2023, , 259-290.		0
792	Ultrasound-Induced Microbubble Cavitation for Targeted Delivery of MiR-29b Mimic to Treat Cardiac Fibrosis. <i>Ultrasound in Medicine and Biology</i> , 2023, 49, 2573-2580.	1.5	0
794	Nanosponge-mediated oligonucleotide delivery: A cutting-edge technology towards cancer management. <i>Journal of Drug Delivery Science and Technology</i> , 2024, 91, 105226.	3.0	0
795	Non-covalent binding interaction of bioactive coumarin esculetin with calf thymus DNA and yeast transfer RNA: A detailed investigation to decipher the binding affinities, binding location, interacting forces and structural alterations at a molecular level. <i>International Journal of Biological Macromolecules</i> , 2024, 257, 128568.	7.5	0
796	Emerging Futuristic Targeted Therapeutics. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2024, 47, 132-148.	1.3	0
797	Apoptosis Inhibitor 5: A Multifaceted Regulator of Cell Fate. <i>Biomolecules</i> , 2024, 14, 136.	4.0	0
798	Aptamer-Based Targeting of Cancer: A Powerful Tool for Diagnostic and Therapeutic Aims. <i>Biosensors</i> , 2024, 14, 78.	4.7	0
799	The development and technologies of RNA therapeutics. <i>Progress in Molecular Biology and Translational Science</i> , 2024, , 13-39.	1.7	0
800	The landscape of nanoparticle-based siRNA delivery and therapeutic development. <i>Molecular Therapy</i> , 2024, 32, 284-312.	8.2	0

#	ARTICLE	IF	CITATIONS
801	Types of RNA therapeutics. Progress in Molecular Biology and Translational Science, 2024, , 41-63.	1.7	0
802	Cis-Platinum and CXCR4 siRNA Carried with Cellulose Nanopaper Restrain the Biological Effect of Breast Carcinoma Cells. Journal of Biomedical Nanotechnology, 2024, 20, 539-544.	1.1	0
803	A polyamino acid-based phosphatidyl polymer library for <i>in vivo</i> mRNA delivery with spleen targeting ability. Materials Horizons, 0, , .	12.2	0
804	Biomembrane-derived nanoplexes for siRNAs-pioneer innovation in delivery to lung adenocarcinoma. Journal of Nanoparticle Research, 2024, 26, .	1.9	0